PF-06882961
Protocol C3421005Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 4Section 4.2, Scientific Rationale for Study 
Design has been revised to include updates to the description of titration schemes and the rationale for contraception requirements for female participants.
Rationale: Titration scheme description 
aligns with updates to Section 6 and therationale for contraception requirements for female participants has been included for completeness.
Section 4.3, Justification for Dose has been 
revised to reflect that study C3421002 has completed and data are no longer preliminary.
Rationale: C3421002 was completed after 
initial protocol finalization.
Section 4.4, Assessment of Safety and 
Tolerability While Study is Ongoing has been updated to indicate that an interim analysis will occur at least once during study conduct and to also include the minimum timeframe between blinded safety reviews.  The triggers for pausing or stopping active dose(s) were moved to Section 6.6.1, Considerations for Pausing or Stopping Active Dose(s) Based on Observed Safety.
Rationale: The minimum time frame of 
monthly between safety reviews has been added to ensure that there is ample time to prepare all data reports and ensure a timely review of safety data.  The interim analysis of unblinded safety data permits possible updates to study conduct if needed.
Section 5.2, Exclusion Criteria, criterion #15 
has been revised to lower the systolic and diastolic blood  pressure eligibility criteria.  CCI
PF-068829 61
Protocol C3421005
Final Protocol Ame ndment 1 ,
19May 2020
PFIZER C ONFIDENTIAL
Page 9hypo-or hy per-glycemia .
Rationale: This revision 
is made to clarify  
that the blinding of t hese spec ific ana lytes 
does not occur until aft er the scre ening 
period so that eligibility  can be co nfirmed.
Protocol Appendix 3, Section s 10.3.
2, 
Definition of SAE and 10.3.3 , 
Recor ding/Reporting and Fo llow-up of A Es 
and/or SAEs has been revised to align with 
Pfizer requirements.
Protocol Appendix 4 ,Section 10.4.2, Female 
Participant Reproductiv e Inclusi on C riteria
and Section 10.4.4, Contraception Methods 
have beenrevised to clarify  permitted female 
participant i nclusion criteria and 
contrace ption requirements in cases where 
contraception is highly user depend ent.  
Additionally , the requirement of femal es to 
not dona te eggs has been removed.
Rationale: This revision 
is made to ali gn 
with requirements when using 
contraception that is highly  user 
depende nt.PF-06882961 does not have 
risk of genotoxi city; as such t he 
requirement of fema les to not d onate egg s 
has been re moved .
Protocol Appendi x
9, ProposedChronology  
of Procedures has been revised to clar ify that 
body  weight should be obtained prior to 
dosing and food consumption.
Rationale: Body weight is a secondary  
endpoint and must be obtained un der 
standardized cond itions.
Original pr otocol 03 Ap ril 2019 N/A
This amendment incorporate s all revision s to date, incl uding amendments ma de at the 
request of country  health authorities and IRBs/EC s.

PF-068829 61
Protocol C3421005
Final Protocol Ame ndment 1 ,
19May 2020
PFIZER C ONFIDENTIAL
Page 10TABLE OF CON TENTS
LIST OF TABLES ...................................................................................................................14
1. PROTOCOL  SUMMARY ...................................................................................................15
1.1.Synopsis ..................................................................................................................15
1.2. Schema ....................................................................................................................20
1.3. Schedule of Activities (SoA) ...................................................................................21
2. INTRODUCTION ...............................................................................................................23
2.1. Study  Rationale .......................................................................................................23
2.2. Background .............................................................................................................23
2.2.1. Nonclinical Overview .................................................................................24
2.2.1.1. N onclinical Pharmacology ........................................................24
2.2.1.2. Nonclinical Pharmacokinetics and Metabolism ........................24
2.2.1.3. Nonclinic al Safety .....................................................................25
2.2.2. Clinical Overview .......................................................................................26
2.2.2.1. Clinical Safety ...........................................................................26
2.2.2.2. Clinical Pharmacokineti cs.........................................................27
2.3. Benefit/Risk Assessment
.........................................................................................27
3. OBJECTI VES, ESTIM
ANDS, AND ENDPOINTS ...........................................................28
4. STUDY DESIGN .................................................................................................................30
4.1. Overall Design .........................................................................................................30
4.2. Scientific Rationale for Study  Design .....................................................................31
4.3. Justification for Dose ..............................................................................................32
4.4. Assessment of Safety and Tolerabilit y While Study  is Ongoing ............................33
4.5. End of Study Definition ................................ ................................ .......................... 33
5. STUDY POPUL ATION ......................................................................................................33
5.1. I nclusion Criteria .....................................................................................................33
5.2. Exclusion Criteria ....................................................................................................34
5.3. L ifesty le Considerations ..........................................................................................37
5.3.1. Dietary  Restrictions ....................................................................................37
5.3.2. Alcohol, Caffeine and Tobacco ..................................................................38

PF-06882961
Protocol C3421005Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 115.3.3. Physical  Activity.........................................................................................38
5.3.4. Contraception..............................................................................................38
5.4. Screen Failures ........................................................................................................38
6. STUDY INTERVENTION..................................................................................................39
6.1. Study Intervention(s) Administered ........................................................................396.2. Preparation/Handling/Storage/Accountability ........................................................40
6.2.1. Preparation and Dispensing ........................................................................42
6.3. Measures to Minimize Bias: Randomization and Blinding.....................................42
6.3.1. Allocation to Investigational Product .........................................................426.3.2. Breaking the Blind......................................................................................43
6.4. Study Intervention Compliance...............................................................................436.5. Concomitant Therapy..............................................................................................43
6.5.1. Metformin...................................................................................................446.5.2. Medications for Glycemic Control .............................................................446.5.3. Antihypertensive Medications....................................................................446.5.4. Lipid Modify ing Medications.....................................................................44
6.5.5. Glycemic Rescue Medicine ........................................................................45
6.6. Dose Modification...................................................................................................45
6.6.1. Considerations for Pausing or Stopping Active Dose(s) Based on 
Observed Safety...............................................................................................45
6.7. Intervention After the End of the Study..................................................................45
7. DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT 
DISCONTINUATION/ WITHDRAWAL...........................................................................46
7.1. Discontinuation of Study Intervention ....................................................................46
7.1.1. Criteria for Discontinuation........................................................................46
7.2. Participant Discontinuation/Withdrawal From the Study .......................................467.3. Lost to Follow-up ....................................................................................................47
8. STUDY ASSESSMENTS AND PROCEDURES...............................................................48
8.1. Efficacy Assessments..............................................................................................49
8.1.1. Primary Efficacy Parameter: HbA1c ..........................................................498.1.2. Secondary  Efficacy Parameters .............................................49
8.2. Safety Assessments .................................................................................................49
CCI
PF-06882961
Protocol C3421005Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 128.2.1. Physical Examinations................................................................................49
8.2.2. Body We ight...............................................................................................50
8.2.3. Vital Signs ..................................................................................................50
8.2.3.1. Blood Pressure and Pulse Rate..................................................50
8.2.4. Electrocardiograms.....................................................................................518.2.5. Management of Glycemic Control .............................................................51
8.2.5.1. Home Glucose Monitoring........................................................528.2.5.2. Management of Hypoglycemia .................................................528.2.5.3. Management of Hypergl ycemia ................................................54
8.2.6. Clinical Laboratory Assessments ...............................................................548.2.7. Pregnancy Testing ......................................................................................55
8.3. Adverse Events and Serious Adverse Events..........................................................55
8.3.1. Time Period and Frequency for Collecting AE and SAE Information.......56
8.3.1.1. Reporting SAEs to Pfizer Safety...............................................568.3.1.2. Recording Nonserious AEs and SAEs on the CRF...................56
8.3.2. Method of Detecting AEs and SAEs ..........................................................568.3.3. Follow-up of AEs and SAEs.......................................................................578.3.4. Regulatory Reporting Requirements for SAEs...........................................578.3.5. Exposure During Pregnancy or Breastfeeding, and Occupational 
Exposure ..........................................................................................................57
8.3.5.1. Exposure During Pregnancy......................................................578.3.5.2. Exposure During Breastfeeding ................................................588.3.5.3. Occupational Exposure .............................................................58
8.3.6. Medication Errors .......................................................................................58
8.4. Treatment of Overdose............................................................................................59
8.6. Pharmaco dynamics..................................................................................................60
CCI
CCI
PF-06882961
Protocol C3421005Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 138.9. Health Economics ...................................................................................................62
9. STATISTICAL C ONSIDERATIONS ................................................................................62
9.1. Estimands and Statistical Hypotheses .....................................................................62
9.1.1. Estimands....................................................................................................62
9.2. Sample Size Determination.....................................................................................649.3. Populations for Analysis .........................................................................................659.4. Statistical Analyses .................................................................................................65
9.4.1. Efficacy Analyses .......................................................................................669.4.2. Safety Analys es ..........................................................................................67
9.4.2.1. Electrocardiogram Analyses......................................................67
9.5. Interim Analyses .....................................................................................................68
9.5.1. Data Monitoring Committee.......................................................................68
9.6. /PD Unblinding Plan ..........................................................................................68
10. SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS ..........................................................................................................69
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations ...............69
10.1.1. Regulatory and Ethical Considerations ....................................................69
10.1.1.1. Reporting of Safety Issues and Serious Breaches of the 
Protocol or ICH GCP.........................................................................69
10.1.2. Financial Disclosure .................................................................................7010.1.3. Informed Consent Process ........................................................................7010.1.4. Data Protection .........................................................................................7110.1.5. Dissemination of Clinical Study Data ......................................................7110.1.6. Data Qualit y Assurance ............................................................................73
10.1.7. Source Documents....................................................................................7410.1.8. Study and Site Closure..............................................................................74
10.1.9. Publication Policy.....................................................................................75CCI
CCI
CC
I
PF-06882961
Protocol C3421005Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 1410.1.10. Sponsor’s Qualified Medical Personnel .................................................76
10.2. Appendix 2: Clinical Laboratory Tests .................................................................7710.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow-up, and Reporting ......................................................................80
10.3.1. Definition of AE .......................................................................................8010.3.2. Definition of SAE.....................................................................................8110.3.3. Recording/Reporting and Follow-up of AEs and/or SAEs.......................8210.3.4. Reporting of SAEs....................................................................................85
10.4. Appendix 4: Contraceptive Guidance and Collection of Pregnancy 
Information ................................................................................................................87
10.4.1. Male Participant Reproductive Inclusion Criteria ....................................8710.4.2. Female Participant Reproductive Inclusion Criteria.................................8710.4.3. Woman of Childbearing Potential (WOCBP) ..........................................8710.4.4. Contraception Methods.............................................................................88
10.6. Appendix 6: Liver Safety: Suggested Actions and Follow-up Assessments ........93
10.7. Appendix 7: ECG Findings of Potential Clinical Concern ...................................9510.8. Appendix 8: Prohibited Prior/Concomitant Medications......................................9710.9. Appendix 9: Proposed Chronology of Procedures................................................9910.10. Appendix 10: Abbreviations .............................................................................100
11. REFERENCES ................................................................................................................1 04
LIST OF TABLES
Table 1. Randomized Regimens in Study C3421005 .............................................19Table 2. Titration and Dosing Scheme ...................................................................40Table 3. Randomized Regimens in Study C3421005 .............................................42CCI
PF-06882961
Protocol C3421005Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 151. PROTOCOL SUMMARY 
1.1. SynopsisShort Title: A 16-Week Study to Evaluate the Efficacy and Safety of PF-06882961 in 
Adults with Type 2 Diabetes Mellitus 
RationaleThis multicenter, randomized, double-blind, placebo controlled, parallel group study is being 
conducted to provide data on efficacy, safety, tolerability  of multiple dose levels of PF-06882961 in adults with type 2 diabetes mellitus (T2DM)inadequately controlled on metformin and/or d iet and exercise.  In addition, the study is 
intended to enable selection of efficacious doses for future clinical development of PF-06882961.
CCI
PF-068829 61
Protocol C3421005
Final Protocol Ame ndment 1 ,
19May 2020
PFIZER C ONFIDENTIAL
Page 16Objectives , Estimands, and En dpoints
Objectives Endp oints Estimands
Prima ry: Primary: Primary:
To compa re the effect of multiple dose 
levels of PF-0688 2961 versus pl aceboon
glycated hemoglo bin (HbA1c )in 
participants with T2DM on stable dos es
of metformin and/or diet and exercise .Change from baseline inHbA1c
at Week 16.Estimand 1A: This estimand is inte nded to 
provide a population level estim ate of t he 
mean treatm ent effect (PF -06882961 
versus placebo) on a continuous endpoin t 
in particip ants on stable doses of 
metformin and/or diet and exercise 
without the benef itof gly cemic rescue 
medication while on treatment.
Secondary: Secondary: Secon dary: 
To compare the effect of m ultipl e dose 
levels of PF -068829 61 versus placebo o n 
glycemic co ntrolin participants with 
T2DM on stabl e doses of metformin 
and/ordiet and exercise .Response as de fined byan
HbA1c <7% at Week16.Estimand 2: This estima nd is in tended to 
provide a popula tion l evel es timate of the 
odds ratio treatment eff ect(PF-06882 961
versus placebo) on a binary responde r 
endpoint in participa nts on stable doses of
metformin and/o r dietand exerci se 
without the benefit of glycemic rescu e 
medica tion.
Change from baseli ne in HbA1c 
at Weeks 2, 4, 6, 8 and 12.Estiman d1Aasabove.
Change from baseline in fasting 
plasma g lucose at Weeks, 2, 4, 
6,8,12and 16.Estim and 3: This esti mand will be the 
same as 1A.
To compare the effect of mu ltiple d ose 
levels of PF-06882961 versus placeb o on
body weight in participants with T2DM 
on stabl e doses of metformin and/or diet 
and exe rcise.Change from base linein body 
weight atWeeks 2, 4, 6, 8, 12 
and 16.Estiman d 4: This estimand will be the 
same as 1A.
To characteriz e the safety and 
tolerability of multiple do se levels of 
PF-06882961 adminis tered to 
participants with T2DM on stabl e doses 
of metformin an d/ordiet and exercise .Incidence of t reatment 
emergent adverse events 
[adverse events ( AEs)and
seriou s adverse even ts (SAEs )], 
clinic al labo ratory 
abnormalitie s, vital signs 
(blood pressure a ndpulse rate)
and electrocardiogram ( ECG)
parameters (heart ra te, QT, 
QTcF,PR and Q RS intervals) .There are no defin ed estimands for these 
endpoints and the y will b e analyzed using 
Pfizer da ta sta ndards asapplicable.

PF-068829 61
Protocol C3421005
Final Protocol Ame ndment 1 ,
19May 2020
PFIZER C ONFIDENTIAL
Page 18OverallDesign
This Phase 2b, multi -center, randomized, double -blind, placebo -controlled, 6 -arm, parallel 
group, stud ywill assess efficacy  and safet y of twic e daily  administrat ion of PF -06882961 in 
adult partic i
pantswith T2DM inadequ ately con trolle d on m etformin monotherap y or d iet and 
exercise alone.  At least 80% of the enrolled participants are r equired to be on metf ormin 
prior to screening.  While a small er proportion of pa rticipants managing their T2DM with
dietand exerc ise onl yis permi tted, this p roportion should be no mo re than approximately  
20% of the enrolled participants.
Following the sc reening period to confir m eligibility (up to 4-weeks), the st udy will consist 
ofa 2-week placebo run -in period, p r ior to randomiz ation on Day 1.  The tr eatmen t period 
will be 16 weeks , followed by  an approximate 4-week follow -up.  The total duration of 
participation in the st udyis approximately  22 weeks, not inclu ding the screening period .  
Dosing will occur with food twi ce dail y (BID) , and up to 6 weeks of the 16-week dosing 
duration will be used for dose titration to maximize tolerability  of PF -06882961 . 
Number of Particip ants
Approximately  400 particip ants (approximately  67participants per treatment arm) will be
randomized to e nsure completion of app roxima tely300participants (ap proximately  
50 participants per treatment arm).  Randomization will be s tratified according t o background 
diabetes treatment (presenc e or absence of met formin therapy ).
Intervention Group
s and Duration
Followi ng the sc reenin g peri od, the study  will consis t of a 2- week placebo run -in period, 
prior to randomization on Day 1.  The t reatment period w illbe 16 weeks.
Participants w ill take 4tablets of invest igational product (IP)(PF-06882961 or m atching 
placebo) i
n the mor ning with food and in the evening wit h food, for a total of 8 tablets of IP 
daily .  The same dosing paradigm wi llbe used du ring the placebo run -in pe riod.  Morning 
dosing will occur with food at the site at Visits 2 through 9.  Participants wil l be in structed to 
arrive a
tthesite in the faste d stat e, bring their IP with them, and to dela y self -administration 
of IP on schedule d visit days u ntilthey arrive for their c linic visit.

PF-06882961
Protocol C3421005Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 19Table 1. Randomized Regimens in Study C3421005
Regimen Regimen Description 
(dosed twice-daily)Number of PF-06882961 tablets Number of 
PF-06882961-matching 
placebo tablets
2.5 mg 10 mg 40 mg 100 mg 2.5 mg 10/40/100 mg
A Placebo - - - - 1 3
B PF-06882961 – 2.5 mg 1 - - - - 3
C PF-06882961 – 10 mg - 1 - - 1 2
D PF-06882961 – 40 mg - - 1 - 1 2
E PF-06882961 – 80 mg - - 2 - 1 1
F PF-06882961 – 120 mg - 2 - 1 1 -
Per the study estimands, if IP is permanently discontinued, the participant will remain in the 
study and continue to follow all protocol specified visits and procedures according to the SoA with the exception of dosing activities 
Data Monitoring Committee
This study will use an internal review committee (IRC); an external data monitoring 
committee will not be utilized. An IRC charter will be developed to govern the details of any interim analysis and IRC operations.  
Statistical MethodsDetailed methodology for summary and statistical analyses of the data collected in this study 
is outlined in Section 9 and further detailed in a statistical analysis plan (SAP), which will be 
maintained by the sponsor.
The primary estimand will be the population average treatment effect on the change from 
baseline in HbA1c at Week 16 of PF-06882961 compared to placebo in the absence of glycemic rescue medication while on treatment and stable doses of background metformin and/or diet and exercise. Measurements after initiation of glycemic rescue medication ordiscontinuation of IP will be censored and treated as missing data.  Missing data due to censoring, study withdrawal or other reasons (eg, laboratory failure) will have data imputed 
based on a missing at random (MAR) assumption. The population-based treatment effect will be the difference in the mean change from baseline in each PF-06882961 arm compared to placebo.  
A secondary estimand will be the population odds ratio of the treatment effect of achieving 
HbA1c <7% at Week 16 of PF-06882961 compared to placebo in the absence of glycemic rescue medication in participants while on treatment and on stable doses of background metformin and/or diet and exercise.  All other key secondary continuous clinical endpoints will be analyzed using the primary estimand described above.CCI
PF-068829 61
Protocol C3421005
Final Protocol Ame ndment 1 ,
19May 2020
PFIZER C ONFIDENTIAL
Page 20The primary  anal ysisof the prima ryendpoint will be cond ucted usi ng a mixe d mode l 
repeated me asures ( MMRM ) anal ysis of the change from baseline in HbA1c through 
Week 16.The primary  analysis will include all participants random ly assign ed to I P and 
who take at least 1 dose of IP. The M
MRM will inc lude treatme nt, time, strata ( metformin 
vs. diet and exercise alone) and treatment -by-time interaction as fixed effects, baseline as a 
covari ate and the baseline -by-time interaction wi th time f itted as a repea ted effect and 
partic ipant as a ran dom effect. An u nstruct ured corr elation m atrix will be used, and the 
Kenward -Roger approximation will 
be us ed for estimating degrees of freedom for the model 
parameters. Missing values will be i mputed as part of t he MMR Mmodel assumptions a nd 
no adjustme nts will be 
made for mul tiplicity .
1.2.Schema

PF-06882961
Protocol C3421005Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 232. INTRODUCTION
Glucagon-like peptide-1 (GLP-1) is a ne uroendocrine hormone that is predominantly 
released from the small intestine in response to food intake.1  GLP-1 activation of the GLP-1
receptor (GLP-1R) stimulates insulin release, inhibits glucagon secretion in a glucose-dependent manner, and delays gastric emptying.
2,3  In addition, GLP-1 has been shown to 
increase satiety and suppress food intake.4  PF-06882961 is an orally administered, small 
molecule GLP-1R agonist that has been demonstrated, in nonclinical models, to stimulate glucose-dependent insulin release and suppress food intake with equiv alent efficacy to an 
injectable peptide GLP-1R agonist approved for the treatment of T2DM.
PF-06882961 is an oral GLP-1R agonist that is currently being investigated as an adjunct to 
diet and exercise to improve glycemic control in adult participants with T2DM.
2.1. Study Rationale 
This multicenter, Phase 2b, randomized, double-blind, placebo controlled, parallel group 
study is being conducted to provide data on efficacy, safety, tolerability  of multiple dose levels of PF-06882961 in adults with T2DM inadequately controlled on metforminand/or diet and exercise. In addition, the study is intended to enable selection of efficaciousdoses for future clinical development of PF-06882961.
2.2. Background 
The increase in the global prevalence of T2DM is largely attributed to rising rates of excess 
body weight and obesity.
5  T2DM is estimated to affect more than 424 million people 
worldwide,6and the prevalence of T2DM within the United States (US) is estimated to range 
from 12 to 14%.7  T2DM is characterized by insulin resistance, a disorder in which cells do 
not respond effectively to insulin, resulting in higher blood glucose levels.  Elevated blood glucose levels and increasing severity of insulin resistance result in the need for more insulin 
over time, eventually resulting in progressive pancreatic β-cell failure.
8  Patients with poorly 
controlled T2DM have an increased risk of developing complications associated with both microvascular and macrovascular disease, including nephropathy, neuropathy, retinopathy, cardiovascular disease and stroke; and are at 2 to 4 times increased risk of mortality than adults who do not have diabetes.
9  While existing pharmacological options for the treatment 
of diabetes may provide satisfactory glycemic control for some patients, there remains a largenumber of patients who do not achieve target glycated hemoglobin (HbA1c) levels, suggesting a need for additional therapeutic options.
Marketed injectable GLP-1R agonists have demonstrated robust glycemic efficacy, weight 
loss, and cardiovascular safety, with at least one marketed agent demonstrating cardiovascular benefit.
10  Based on the clinical history of injectable GLP-1R agonists, an oral 
GLP-1R agonist is expected to improve glucose control and reduce HbA1c levels in patients with T2DM, while decreasing food intake and body weight and avoiding the subcutaneous injection required by currently available peptidic GLP-1R agonists.CCI
PF-068829 61
Protocol C3421005
Final Protocol Ame ndment 1 ,
19May 2020
PFIZER C ONFIDENTIAL
Page 283.OBJEC TIVES, ESTIMANDS, AND ENDP OINTS
Objectives Endpo ints Estimands
Prim ary: Prim ary: Prim ary: 
To compare the eff ect of multiple 
dose levels of PF -06882961 vers us
placebo onHbA1c in pa rticipants 
with T2DM on stable doses of 
metformin and/or diet and exerci se.Change from basel ine in 
HbA 1c at W eek 16.Estimand 1A: This estimand is 
intended to provide a population lev el 
estimate of the mean treatment effec t 
(PF-068829 61 versus placebo) on a 
continuous endpoint in participants on 
stable doses of metform in and/ or diet 
and exercise witho ut the benefit of 
glyce
mic res cue medicati on while on 
treatment.
Secondary: Secondar y: Secondary: 
To compare the effect o f multiple
dose levels of PF -06882961 versus 
placebo on glycemic control in 
participants with T2DM on sta ble 
doses of metformi n and /or d iet and 
exercise.Respons e as defined bya
n
HbA1c <7% at Week 16.Estimand 2: Thi s estimand is intended 
to provide a pop ulation level estimate 
of the odd s ratio treatment effect 
(PF-06882961 versus placebo) on a 
binary respon der endpoint in 
participan ts on stable doses of 
metform in and/or diet and exercise 
without the benefit of glycem ic rescue 
medication.
Change from bas eline in
HbA1c at Weeks 2, 4, 6, 8 
and 12 .Estimand 1A as above.
Change from baseline in 
fasting plasma glucose at 
Weeks 2, 4, 6, 8, 12 and 16.Estiman d3: Thi s estimand w ill be the 
same as 1A.
To compare the effect of multiple 
dose levels of PF -0688296 1 versus
placebo on body weight i n 
participants with T2DM on stable 
doses of metformin and/or diet and 
exercise.Change from b aseline in
body weight at Weeks 2, 4, 
6, 8, 12 and 16.Estimand 4: This estimand w ill be th e 
same as 1A.
To characterize the safe ty and 
tolerability of multiple d ose levels of 
PF-06882961 administered to 
participants with T2DM on stab le 
doses of metformin and/or di et and 
exercise.Incidenc e of treatment 
emergent adverse events 
(AEs andSAEs), c linical 
laboratory abnormalities, 
vital signs (blood pressure 
and pulse rate) and ECG 
parameters (heart rate, QT, 
QTcF, PR and QRS 
interv als).There are no defined e stima nds f or 
these endpoint sand th ey will be 
analyzed using Pfizer data standards 
as appli cable.

PF-068829 61
Protocol C3421005
Final Protocol Ame ndment 1 ,
19May 2020
PFIZER C ONFIDENTIAL
Page 334.4.Assessment of Safety and Tolerability While Study is Ongoing
During stud y conduct, after approximately eve ry 25% of th e total planned rand omizations
[for example: 100 subjects (25 %), 200 subjects (50%), and 300 subjects (75%), of planned 
approximatel y 400 subjects], blinded safet y review will be conducted by selected members 
of the Sponsor’s study  team .Blinded safet y reviews will be separated by  at least one month 
from the previ ous review. AnInterim Anal ysis(IA) of the unblinded safety  data by  the IRC 
will occur at least once while the study  is on going, as de scribed in Section 9.5.
4.5. End of Study Definition
A participant is considered to have complete d the study  if he/she has completed all phases of 
the study  includin gthefollow -up visit (Visit 11), approxim ately 28 to 35 dayspost last dose 
of IP
.
The e nd of t he stud y is defined as the date of the last visit (Visit 11 ), by the last participant 
across all sites gl obally .
5.STUDY POPULATION
This study  can fulf ill its obj ective s only  if appropriate participant s are enrolled.  The
following eligibility  criteri aare de signed to select participant s for whom participation in the 
study  is considered appropriate .  All releva nt medical and nonmedical conditions should be 
taken in
to consideration when deciding whether a p articular partici pant is suitable for this 
protocol.
Prospective approval of protocol deviations to recruitment and enrollment criteria ,also 
known as protocol waivers or exemptions, is not permitted .
5.1.
Inclusion Cr iteria
Participa nts are eligible to be inc luded in the stud y only if all of the following criter ia appl y:
Age and Sex :
1.
Male or female participants between the ages of 18 (or the minimum co untry -specifi c 
age of consent if >18) and 75 years, inclusive, at Vi sit1.
Refer to 
Appendix 4 for reproducti ve crit eria for male ( Section 10.4.1) a nd female 
(Section 10.4.2) participants.
Type of P articipant and Di sease Characteristics:
2.
Patients with T2DM who are treated with metfo rmin and/or diet and exercise. 
For participants taking metfo rmin, the m etformin dose must have beenstable for 
at lea st 60 day s prior to the scr eening visit (Visit 1).

PF-068829 61
Protocol C3421005
Final Protocol Ame ndment 1 ,
19May 2020
PFIZER C ONFIDENTIAL
Page 34Enrollment of parti cipants on diet and exercise o nly(ie,no anti -diabetic 
medications) will be limited to ≤20% of total participant population.
3.HbA1 c ≥7% and ≤10.5 % at screening (Visit 1) as assessed b y the stud y specific
laborator y and confirmed by a singl e repeat test, if de emed necessary .  
4.
Participants who are willing and able to compl y with all scheduled visits, treatment 
plan, laboratory  tests, lifesty le considerations, and other study  procedures
, including 
theability to perf orm self -tests of blood su gar regularly  (see Section 8.2.5.1) for the
duration of the study  and maintenance of study  specific glucose logs for the duration 
of participation in the study .
Body Mass Index (BMI) and Weight:
5.
Total body  weight >50kg (110 lb) with BMI of 24.5 to 4 5.4kg/m2(for sites in North 
America and Europe) o r BMI 22.5 to 45.4 kg/m2(for sites in Asia) .  Body  weight 
must have been stable (<5% change) for 90days pri
or to screening (Visit 1) as per 
participa nt report .
Inform edConsent:
6.Capable of giving signed informed consent as 
described in Appendix 1 ,which
includes compliance with the requirements and restrictions listed in the inform ed 
consent document (ICD) and in this proto col.
5.2. Exclusion Criteria
Partic ipants a re excluded from the study  if any  of the following criteria apply :
Medical Conditions:
1.Any acute or chronic medical or ps ychiatric condition including recent ( withi nthe 
past year) or active suicidal ideation or behavi oror laboratory  abnormality  that may
increase the risk associated with study
 participat ion or IPadministration or may  
interfere with the interpretation of study results and, in the judgment of th e 
investigator, would make the participant inappropriate for entry into this study .
2.Any conditio npossibly  affecting drug absorption (eg, prior bar iatric surgery , 
gastrectom y, or an y area of intestinal resection, active inflammatory  bowel disease or 
pancre atic 
insufficien cy).
3.Diagnosis of t ype 1 di abetes mellitus orsecondary  forms of diabetes .
4.Histor y of m yocardial infarction, unstable angina, arter ial revascularization, stroke, 
New York Heart Association Functional Class II -IV heart failure, or transient 
ische mic attack within 6 months of screeni ng (Visit 1).

PF-068829 61
Protocol C3421005
Final Protocol Ame ndment 1 ,
19May 2020
PFIZER C ONFIDENTIAL
Page 355.Any malignancy  not considered cur ed (exc ept basal cell carcinoma and squamous cell 
carcinom a of the skin); a subject is considered cured if there has been no evidence of 
cancer recurrence in the previous 5 years.
6. Per sonal or famil y history of medullary  thyroid carcinoma (MTC) or multiple 
endocri ne neoplasia s yndrome type 2 (MEN2), or subjects wi th suspected MTC per 
the 
investigator’s judgment .
7.Acute pancreatitis or history  of chronic pancreatitis.
8.Symptomat ic gallblad der disease.
9.Participants with a known medi cal history ofactive prolifer ative r etinopathy  and/or 
macular edema.
10. Participants with a known medical history  of active liver disease (other than non -
alcoholic hepatic steatosis), including chron ic active hepati tis B or C, or primary  
biliary cirrhosis.
11.
Participants with known history of huma n immunodeficiency  virus ( HIV).
Prior/Concomitant Therapy:
12.See Appendix 8for details regarding prohibited prior/ concom itant medic ations.
Prior/Concurrent C linical Study Exp erience:
13. Previous administration with an investigational drug within 30 days (or as dete rmined 
by the local requirement) or 5 half-
lives preceding the first dose of IPused in this 
study  (whichever is longer). 
14.Known prior participation in
a trial involving PF-06882961 or known intoler ance to a 
GLP-1R agonist.
Diagnostic Assessments:
15.Screenin g supine blood pressure ( BP) ≥160 mmHg (s ystolic) or ≥ 100mmHg 
(diastolic), following at least 5 minutes of supine rest.  BP should be 
measured in 
triplicate and the average of the 3 BP values should be used to determine the 
participant’s eligibility .Note: Participants wit h an arm circumference greater than 
the largest cuff size or those with a mid -arm circumference >52 cm are not eligible.

PF-068829 61
Protocol C3421005
Final Protocol Ame ndment 1 ,
19May 2020
PFIZER C ONFIDENTIAL
Page 3616.Screening 12- lead electrocardiogram (ECG) that demonstrates clinicall y relevant 
abnormalities that may  affect participant safet y or int erpretati on of study  results 
(eg,baseline corrected QT interval 
[QTcF] >450 msec, complete left bundle branch 
block [L BBB], signs of an acute or indeterminate -age m yocardial infarction, ST -T 
interval changes suggestive of my ocardial ischemia, second -or thi rd-degree 
atrioventricular [AV] block, or serious brad yarrh ythmias or tach yarrh ythmias).  
If QTc Fexceeds 450 msec, or QRS exceeds 120 msec, the ECG should be 
repeated 2 more times and the average of the 3 QTcFor QRS values should be 
used to determine the partic ipant’s eligibility .  
17.A positive urine drug test. Note: Participants who have been medicall y prescribed 
opiates/ opioids or benzodiazepines and report the use of these drugs to the 
investigator at screening (Visit 1) may  be allowed to participat ewith not ification to 
the sponsor.  
18.Participants with ANY of the following abnormalities in clinical laboratory  tests at 
screening, as assessed b y the study  specific laboratory  and confirmed b y a single 
repeat test, if deemed necessary :
Aspartate aminotr ansferase (AST) or alanine aminotransferase (ALT) level 
≥2times the upper limit of normal (ULN).
Total bilirubin level ≥ 1.5 times the UL N.
Fasting C peptide <0.8 ng/mL.
TSH >1.5 times the ULN.
Serum calcitonin > the ULN.
Amy lase or lipase > the ULN.
Fasting 
plasma blood glucose >270 mg/dL (15mmol/L) at screening (Visit 1) or 
placebo run -in (Visit 2).
Estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2as calculated by  
the 
Chronic Kidney  Disease Epidemiology  Collaboration (CKD -EPI) equation .14
Other Exclusi ons:
19.Compliance of < 89% based on pill count (See Section 6.4)during the 2-week placebo 
run-in period, as assessed prior to randomization on Day 1.

PF-06882961
Protocol C3421005Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 3720. History of regular alcohol consumption exceeding 7 drinks/week for female subjects 
or 14 drinks/week for male subjects (1 drink = 5 ounces [150 mL] of wine or 12 ounces [360 mL] of beer or 1.5 ounces [45 mL] of hard liquor) within 6 months prior to screening (Visit 1).
21. Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or 
more within 60 days prior to randomization (Day 1).
22. Unwilling or unable to comply with the criteria in the Lifestyle Considerations
section of this protocol.
23. Investigator site staff members directly involved in the conduct of the study and their 
family members, site staff members otherwise supervised by the investigator, or Pfizer employees, including their family members, directly involved in the conduct of the study.
5.3. Lifestyle Considerations
5.3.1. Dietary Restrictions
•Participants must abstain from all food and drink (except water) for at least 
8 (preferably 10) hours prior to any body wei ght measurements and blood sample 
collections
•Water may be consumed as desired (ad libitum).
•IP must be administered BID in the morning and evening with food, approximately 
10-12 hours apart.
•On scheduled visits to the site, in the morning, from Visit 2 through Visit 9, 
participants should be instructed to arrive without having food/breakfast, 
self-administration of IP, andmorning dose of concomitant medication for the control 
of glycemia, if applicable, for the given day. Note: Participants may take their morning dose of antihypertensive and/or lipid modifying medication per their usual routine, if applicable.
•At Visit 2 through Visit 9, inclusive, the above-mentioned medications will be 
administered at the site with food.  
•Participants will be counseled on appropriate dietary and lifestyle guidelines for 
T2DM at Visit 2 and asked to maintain these guidelines throughout participation in 
the study.  Counseling on dietary guidelines should be in accordance with local medical standards of care for patients with T2DM. Note; Participation in formal weight loss programs should be avoided during participation in this study.CCI
PF-068829 61
Protocol C3421005
Final Protocol Ame ndment 1 ,
19May 2020
PFIZER C ONFIDENTIAL
Page 385.3.2. Alcohol, Caffeine and Tobacco
Intake of alcohol is permitted in moderation (refer to exclusion criterion 20for 
acceptable amount of alco hol consumption).
Caffe ine co ntaining products will be permitted durin g the stud y with the following 
restrictions: caffeine containing products may  not be consumed within 1 hour prior to 
measuring vital signs and ECGs.
Use of nicotine -containing products i s permitted in this stu dy with the f ollowing 
restrictions: nicotine -containing pro ducts may  not be used within 1 hour prior to 
measuring vital signs and ECGs. 
5.3.3. Physical Activity
Participants will not be permitted to perf orm phy sically  strenuous exercise (f or example: 
heav y lifti ng, we ighttraining, cal isthe nics and aerobics) within 48 hours prior to blood 
sample collections; walking at a normal pace is permitted.
5.3.4. Contraception
The investigator or his or her designee, in 
consultation with the participant , will confirm that 
female participants have selec ted a n appropriate meth od of contra ception from the permitted 
list of contraception methods (see Appendix 4 ,Section 10.4.4 )and w illconfirm that t he 
participant has been instructed in its consistent and correct use.  At time points indicated in 
the SoA the investigator or designee will inform the participant of the need to use h ighly 
effective contrac eption consistently  and corre ctly and document the conversa tion and the 
participant ’s affirmation in the participant ’s chart ( participant s need to affirm their consistent 
and correct use of at least 1 of the selected methods of contr aception).  In addition , the 
investigator or de signe e will instruct th e participan tto call immediately  if the selected 
contraception method is discontinued or if pregnancy  is known or suspected in the participant
or par tner.
5.4.Screen Failures
Screen failure s are defined as partic ipants whoconsent to pa rticipate in the clinic al study  but
are not subsequently  randomly  assigned to IP. A minimal set of screen failure information is 
required to ensure transparent reporting of screen failure participants to meet the 
Consolidated Stand ards o f Reporting Trials (CON SORT) publishing r equirements and to 
respond to queries from regulatory  authorities. Minimal information includes demography , 
screen failure details, eligibility  crite ria, and any  SAE.
A participant who qualified for this stud y but didnotenroll wit hin the protocol prescr ibed 
screeni ng period may  be re -screened.  All screening procedures must be repeated, and the 
participant assigned a new 8
-digit study- specific subjec tidentification (SSID) number. 

PF-068829 61
Protocol C3421005
Final Protocol Ame ndment 1 ,
19May 2020
PFIZER C ONFIDENTIAL
Page 396.STU DY INTERVENTION
Study  interventi on is defined a s anyinvestigational i ntervention( s), marketed product(s), 
placebo, or medical device(s) intended to be administered to a study  participant according to 
the study  protocol.
For the purposes of this protocol, the term IPmay be used synonymouslywith study
intervention.   For thi s study , the IP is PF - 06882961 and matching placebo tablets; and will be 
administered orall y BID with food .
Treatment Phase I
Pwill be packaged in blister cards cont aining blinded PF -06882961 or 
mat
ching placebo f or oral administra tion.  Treat ment assignment will be blinded, and blister 
cards will be labeled according to local regulatory requirements.   For the placebo run -in, 
pl
acebo tablets will be packaged in blister cards accord ing to local regulatory requirements.  
For participa nts taking metformin, they will continue taking their own metformin medication 
at the same total dail y dose that was prescribed prior to s
tudy entry , except in circumstances 
wher e a dose change is deemed medica l ly necessary .
6.1. S tudy Intervention( s) Administe red
Intervention Name PF-06882961 Placebo for PF -06882961
ARM Nam e Active Placebo
Type Drug Drug
Dose Form ulation Tablet Tablet
Unit Do se Strengths 2.5 mg, 10 mg, 40 mg and 1 00 mg Not applicabl e
TargetDosage Lev els
(achi eved upon titratio n)2.5, 10, 4 0, 80, 120 mg BID 0 mg BID
Route of Adm inistration Oral Oral
Sourcing Provided centrally by the sponsor.  
Refer to the Investigational Product 
Manual.Provided centrally by th e sponsor.  
Refer t o the Investi gational Product
Manual.  
Packa ging and Labe ling Study intervention will be provided 
in blister packs.  Each blister pack 
will be labeled as required per 
country requirement.
Blinded labels w ill be utilized for 
placebo ru n-in, titration and stabl e 
dosin gblister packs.Study interventi on will be pr ovided in 
blister packs.  Each blister pack will be 
labeled as required per country 
requirement.
Blinded labels w ill be utilized for 
placebo run -in, titration and stable 
dosing blister packs.
Participa nts wil ltake 4 tablets of IP (PF -06882961 or matchin gplacebo) inthe m orning with 
food and 4 tablets of IP inthe 
evening with food, for atotal of 8 tablets of IP dail y.  
Participants will swallow the I P whole, and will not crush, chew, break , or dissolve the IP 
prior to swallowing.  
The same dosing paradigm will be used during the pla cebo r un-in 
period .  

PF-068829 61
Protocol C3421005
Final Protocol Ame ndment 1 ,
19May 2020
PFIZER C ONFIDENTIAL
Page 41must be documented an d available upon request.  Data for nonworking days must 
indicate the m inimum and maximum temp erature since previousl y documente dfor all 
site storage locatio ns upon return to business.
3.The investiga tor, institut ion, or the head of the medical institution (where applicable) 
is responsible for study  intervention accountab ility, recon ciliation, and r ecord 
maintenance (ie, receipt, re conciliation, an d final d isposition records). All study  
intervention swill be accou nted for us ing a nIPaccountability  form/rec ord. AllIP 
that is taken home by the pa rticipant, both used and unuse d, must be returned to the 
investigator b y the participan t. 
4.Further guid ance and in formatio n for the final disposition of unuse d study  
interventions ar e provided in the I P manual.
5.Any storage conditions stated in the SRSD wil l be superseded b y the st orage
condit ions stated on t he product label. 
6.Study  intervent ions should be s tored in theiroriginal containers and in accordance 
with the labels
. 
7.Site sta ff will instruct participants on the proper storage requirements for take -home 
study  intervention. 
8.Any excursi ons from the study  intervention label storage cond itions should be
reported to Pfizer upon discovery  along with an y actions taken. The site should 
activel y pursue options for re turning the study  intervention to the storage conditions 
described in the labe ling, as soon as possible. Once an excursion is i dentified, the 
study interventionmust be quarantined and not used unti l Pfizer provides permission 
to use the study  interventio n.  It will not be considered a protocol deviation if Pfizer 
appro ves the use of the study  intervention after the temperature ex cursion. Use of the 
study interven tionprior to Pfizer approval will be considered a protocol deviation. 
Specific details rega rding the definition of an excur sion and information the site 
should re port for each excursion will be provided to the site in t he IP manual.
9. T he sponsor or desig nee will provide guidance on the destruction of u nused study
intervention (eg, at the site). If destruction is authorized to take pla ce at the 
investigator si te, the inve stigator must en sure that the materials are destro yed in 
complianc e with appl icable e nvironmental regulations, institutio nal policy , and an y 
special instructions provided by  Pfizer, and all destruction must be adequatel y 
documented.
Additional detai ls about accountability, storage, destruction ,and excurs ion reporting ca n be 
found in the IP manual.

PF-068829 61
Protocol C3421005
Final Protocol Ame ndment 1 ,
19May 2020
PFIZER C ONFIDENTIAL
Page 426.2.1. Preparation and Dispensing
The IPwill be dispense d using an Interactive Response T echnology  (IRT)drug management 
system at each visit according to the SoA.  A qualified staff member wi ll dispense the IPvia 
unique conta iner numbers in the blister cards pr ovided, in qu antities ap propriate for the stud y 
visit sch edule.  The participant should be instructed to maintain the product in the blister 
cards provided throughout the cour se of dosing and return t he
blister cards to the site at the 
next study visit.
6.3.Measu res to Mini mize Bias: Randomization and Blin ding
Allocation to treatment will occur v ia an IRT system.  A rand omiza tion code using the 
method of random permuted blocks will be utilized to randomize eligible participan
ts in 
1:1:1:1:1:1 ratio (1 to 5 of acti ve dosing r egimens of PF -06882961 or placebo ) prior to the 
first dose of IP.
Partic ipants will be stratified at randomiz ation (Day 1) by the presence or absence of 
metfor min as backgroun d medicat ion.
The sy stem will be programmed with blind- breaking inst ructions.  Refer to Section 6.3.2 for
further deta ils.
6.3.1. Allocat ion to 
Investigational Product
Participants will be randomized to receive o neofthe IP regimen s described in Table3.
Table3. Randomized Regimens in Study C3421 005
Regi men Regim en Description 
(dosed twice -daily)Number of PF
-06882961 tablets Number of 
PF-06882961 -matchin g 
placebo tablets
2.5 m g 10 mg 40mg 100mg 2.5 m g 1 0/40/100 mg
A Placebo - - - - 1 3
B PF-06882961 –2.5mg 1 - - - - 3
C PF-06882961 –10mg - 1 - - 1 2
D PF-06882961 –40 mg - - 1 - 1 2
E PF-0688 2961 –80mg - - 2 - 1 1
F PF-06882961 –120 mg - 2 - 1 1 -
Allocation of par ticipants to treatment groups will proc eed through the use of an IRT s ystem 
(intera ctive Web -based response [ IWR]).The I RTsystem will provide a co nfirm ation r eport 
containing the participant number, randomiza tion number, and dispensabl e unit (DU) or 
container number assigned.  T he confirmati on report m ust be stored in the site’s files . 
IPwill be dispensed at the s tudy visits summarized in the SoA . 
The study -specific I RT reference ma nual and IP manu al will pro vide the contact information 
and further det ails on the u se of the I RT s ystem.

PF-068829 61
Protocol C3421005
Final Protocol Ame ndment 1 ,
19May 2020
PFIZER C ONFIDENTIAL
Page 43In the event of a Qual ity Assurance audit, the auditor (s) will be allowed access to unblinded
IPrecords at the site (s) to verify  that randomization/dispensing has be en done a ccurately.
6.3.2. Breaking the Blind 
The I RT will be programmed w ith blind -breaking instructions. In case of an emergency , the 
investigator 
has the s ole responsibility  for de termining if unblinding of a participant’s 
treatment assignmen t is warranted. Particip ant safety  must alwa ys be the first considerat ion 
in making such a det ermination. If the investigator decides that unblinding is warranted, the
investigator should make every effor
t to contact the sponsor prior to unblinding a 
participant’s treat ment assi gnment unless this c ould delay  further managem ent of the 
participant. If a participant’s treatment ass ignment is unblinded, the sponsor must be notified 
within 24 hours after break ing the blind. The date and reason that the blind was broken must
be recor ded i n the source do cumentation and case repor t form (CRF).
The study -specific I RT reference manual and IP manual will provide the cont act infor mation 
and further detail s on the use of the IRT s ystem.
6.4. Study Intervention Compliance
Participant comp liance wi thIPwill be assess ed at each visit. Complia nce will be a ssessed b y 
counting returned tablets. At V4, which occurs during the first 4 week s of dosing when 
participant s may be rec eiving titrat ed doses as part of their blinded reg imen, sites shou ld 
assess the blister cards f or compliance, however the cards should remain in the possession of 
the participant .  Compliance (as assessed b y tablet coun t) will be defined as 
self
-administra tion, by  the par ticipants, of:
≥89% of the study -supplied placebo administer ed during the place bo run -in period.   
Based on the visit window, for a placebo run -in that is 11
-13 day s, up to 2 missed 
doses are allowed, and for a placebo run -in that is 14 -17 day s, up to 3 mi ssed doses 
are allowed. Participants who do not meet this compl iance threshold are not eli gible 
to be randomized int o the study  (See Section 5.2).
≥80% of the study  su
pplied I P from Day1 through Week16, inclusive.  Investigators 
must clo
sely follow non- compliant, randomized, part icipants in order to enhance their 
adherence to treatment. Any parti cipant who fails to meet the crit erion of 
≥80% compl iance will be re -educated b y the s ite staff on the impor tance of 
compliance with IP.
6.5. C oncomi tant Therapy
Participants in this study  will be allowed to b e on certain concomitant medications that have 
been prescribed .Attempts should be made not to alter t he doses and regimens of the 
background medications afte r random ization and for the duration of pa rticipatio ninthis 
study , except in circumstances wher e a change in dose is deemed medically necessa ry.  An y 
changes must be captured in the CRF. 
Additional ly, man y over -the-counter medications are 
also permitted during this study .  

PF-068829 61
Protocol C3421005
Final Protocol Ame ndment 1 ,
19May 2020
PFIZER C ONFIDENTIAL
Page 44Treatments take n within 28 daysbefore the first dose of IP will be documen ted as prior 
treatment.  Treatments taken after the first dose of I P will be documented as concomitant 
treatment.  
All concomit ant treatments, both prescription and over-the-counter taken during the study 
must be recorded with indication, daily  dose, and start and sto p dates of administration.  All 
participants will be questioned about concomitant treatmen t at each clinic visit. 
See Appendix 8for deta ilsregarding prohi bited concomitant medications.   Sites are
encouraged t o contact the sponsor should there be questions as to whether a medication is 
permitted or prohibited.
6.5.1. Metformin
Atleast 80% of all participants 
are req uired to be taking metformin m onoth erapy prio rto
inclusion in this study
 as listed in Section 5.1.  For participants taking metformi n, this study  
requires th
at participants have been takin g stabl edoses of metformin for at le ast 60 days 
prior to the screening visit.  Participants will continue tak ing their own metformin medication 
at the same total dail y dose that was prescribed prior to study  entry  through the first follow 
up visit (ie, Visit10, W eek17-18) , except in circum stanc es where a change in dose is 
deemed medically  necessary .  For study  visit day s, participants should be instructed to refrain 
from morning dosing at home and t o bring the metformin to the site for dosing at the same
time a stheir blinded I P.  For parti cipan ts taking 
metformin more than once a day , the timing 
should be approximately  the same on each day .  
6.5.2. Medications for Glycemic Control
Aside from metformin, th e use of other medication s for gly cemic control is not p ermitte din 
this study unless the par ticipant meets the protocol defined gl ycemic rescue criteria (see 
Section 8.2.5.3).
6.5.3. Antihypertensive Me dications
The use of back ground antihy pertensive agent(s ) is pe
rmitted unless otherwise noted in 
Appendix 8.  Doses of an tihypertensive agent(s) must be stable for at least 4 weeks prior to 
screening and through out the study , except in circumstances where a change in dose i s
deemed medically  necessary .Anychanges 
indoses of these medications must be captured in 
the CRF. 
6.5.4. Lipid Modifying Medications
The use of background lipid modify ing agents is permitted unle ss otherwise noted in 
Appendix 8. Doses of such lipid modify ing agents must be stable for at least 4 weeks prior 
to screening and throughout the study , except in circumstances where a change in dose is 
deemed m edically  necessary .  An y changes in doses of these medicati ons must be captured in 
the CRF . 

PF-068829 61
Protocol C3421005
Final Protocol Ame ndment 1 ,
19May 2020
PFIZER C ONFIDENTIAL
Page 456.5.5. Glycemic Rescue Medic ine
Participants with hypergly cemia as defined in Section 8.2.5.3 should be offer ed glycemic 
rescue medication as an add on to their randomized trea tment.  
Glycemic r escue medication should be prescribed according to local label and obtained 
locally .  The following glycemic 
rescue medications may  be used: metformin (for those 
participants who were not taking metformin at randomization), sulfony lureas , or sodium 
glucose co -transporter 2 ( SGL T2)inhibitors.  For pa rticipants who were taking a submaximal 
dose of metformin, increasing the metformin dose may  be instituted as glycemic rescue
medication, as long as the dose does not exceed the highest approv ed dose in th e country  of 
participation.
The following medicatio n are notpermitted as gl ycemic rescue medications: GL P-1R 
agonists, DPP -4 inhibitors, amy lin analogues , thiazolediediones (T ZDs) or insulin.
The date of glycemic rescue medication administration as well a s the name and dosage 
regimen of the glycemic rescu e medication must be recorded on the CRF .
Participants receiving glycemic rescue medication should continue to follow all pro tocol 
specified visits and procedures according to the SoA.
There is no rescue therapy to reverse the AEs observed with PF -06882961; standard medical 
supportive care must be provided to manage the AEs. 
Standard medical supportive care must 
be provided to manage the AEs, including administration o f carboh ydrates to treat 
hypoglycemic adverse events (HAE) (see Section 8.2.5.2.1).
6.6.
Dose Modification
6.6.1. Considerations for Pausing or Stopping Active Dose(s) Based on Observed Safety
The decision to stop dosing for 1 or more active dose(s) of P F-06882961 may  be considered 
based on recom mendations from the IRC according to their review of unblinded, study -level
emerging, observed sa fety data ( see Section 9.5) , for reasons such as the following:
More than 50% of participants develo p a moderate or severe AE in the 
gastrointestinal s ystem organ class (SOC) not respons ive to sy mptomatic 
manag ement .
6.7.
Intervention A fter the End of the Study
No intervention will be provided to study  partici pants at the end of the study.

PF-06882961
Protocol C3421005Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 467. DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL
7.1. Discontinuation of Study InterventionIt may be necessary for a participant to permanen tly discontinue IP. If a safety or to lerabi lity 
concern arises, in particular if not responsive to symptomatic management, dosing with double-blinded IP may be stopped in an individual participant at investigator discretion.  
Per the study estimands, if IP is permanently discontinued, the participant will remain in the 
study and continue to follow all protocol specified visits and procedures according to the SoA with the exception of dosing activities  
The site should notify the Sponsor Medical Monitor or Sponsor Clinician if the below criteria 
for permanent discontinuation are met.
Note that discontinuation of IP does not represent withdrawal from the study.See the SoA for data to be collected at the time of intervention discontinuation and follow-up 
and for any further evaluations that need to be completed.
7.1.1. Criteria for Discontinuation
Discontinuation of IP must occur for a participant meeting any of the following conditions: 
•Criteria for a potential Hy’s law case are met (see Appendix 6 ).
•Intent to become pregnant or pregnancy confirmed by serum beta human chorionic 
gonadotropin ( β-hCG) testing.  
7.2. Participant Discontinuation/Withdrawal From the Study
A participant may withdraw from the study at any time at his/her own request, or may be 
withdrawn at any time at the discretion of the investigator for safety, behavioral, compliance, or administrative reasons.
At the time of discontinuing from the study, if possible, an early termination visit should be 
conducted. See the SoA for assessments to be collected at the time of study discontinuation 
and follow-up and for any further evaluations that need to be completed. 
The early termination visit applies only to participants who are randomized and then are 
prematurely withdrawn from the study.  Participants should be questioned regarding their reason for withdrawal.  The participant will be permanently discontinued both from the studyintervention and from the study at that time.CCI
PF-068829 61
Protocol C3421005
Final Protocol Ame ndment 1 ,
19May 2020
PFIZER C ONFIDENTIAL
Page 47If a participant withdraws from the study , he/she ma y request des truction of an y remaining 
samples, but data alre ady generated from the samples will continue to be available, and may  
be used to protect the int egrity  of existing anal yses.  The i nvestigator must document an y 
such requests in the site study  records.
If the participant w ithdraws from the study  and also w ithdraws consent (see below) for 
disclosure of future information, no further evaluations should be performed and no 
additional dat
a should be c ollected.  The sponsor may  retain and continue to u se an y data 
collected befor e such withdrawal of consent.
When a participant withdraws from the study  because of an SAE, the SAE must be recorded 
on the CRF a nd reported on the Clinical Trial ( CT) SAE Repor t.
Lack of completion of all or an y of the withdraw al/earl y term ination proced ures will not be 
viewed as protocol deviations so long as the partic ipant ’s safet y was preserved.
Withdrawal of Consent: 
Particip ants who request to discontinue rec eipt of study treatment will remain in the study  
and must continue to be foll owed for protocol -specified follow -up procedures .  The onl y 
exception to this is w hen a participant specificall y withdraws consent for any furth er contact 
with him or her or perso ns previously authorized by the participant to provide this 
info
rmation.  Par ticipant s should notify  the investigator in writ ing of the decision to 
withdraw consent from future follow -up, whenever possible.  The withdrawa l of consent 
should be explained in detail in th e medical records by  the investigator, as to whethe r the 
withdra wal is only  from further receipt of IPor also f rom study  procedures and/or post 
treatment study  follow -up and entered on the appropriate CRF pa ge.  In the event that vital 
status (whether the participant is alive or dead) is being measured, p ublicl y avail able 
informati on should be used to determine vit al status only  as appropriatel y directed in 
accordance with local law.
7.3.Lost to Fol low-up 
A part icipant will be considered lost to follow -up if he or she repeatedl y fails to return for 
scheduled visits and is unable to be contacted b y the study  site.
The f ollowing actions must be taken if 
a participant fails to return to the clinic for a required 
study visit:
The site must attempt to contact the participant and reschedule the missed visit as soon as 
possible a ndcounsel the participant on the importance of maintaining the assigned visit 
schedule and ascertain whether or not the participant wishes to a nd/or should continue in the 
study ;

PF-068829 61
Protocol C3421005
Final Protocol Ame ndment 1 ,
19May 2020
PFIZER C ONFIDENTIAL
Page 48Before a par ticipant is deemed lost to follow -up, the investiga tor or design eemust 
make e very effort to regain contact with the participant (where possible, 3 telephone 
calls and, if necessary , a certified letter to the participant’s last known mailing 
address or loc al equivalent methods). These contact attempts sho uld be docume nted 
in the pa rticipant’s medical record ;
Should the participant continue to be un reachable, he/she will be considered to have 
withdrawn from th e study . 
Discontinuation of specif ic sites or o f the study  as a whole ishandled as part of Appendix 1.
8.STUDY ASS ESSMENTS AND PROCEDU RES
The invest igator (or an appropriate delegate at the investigator site) mustobtain a signed and 
dated ICD before perform ing an y stud y -specific procedures.  
Study  procedur es and their timing are sum marized in the SoA. Protocol waivers or 
exemptions are not allowed.
Immediate safety  concerns should be discussed with the sponsor immediat ely upon 
occu rrence or awareness to determine if the participant should conti nue or discont inue study  
intervention.
Adherence to the study  design requirements,
including those specified in the SoA, is essential 
and required for stu dy conduct.
All screening evaluations must be completed and revi ewed to confi rmthat potent ial 
participants meet all eligibil ity criteria. The investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibi lity or recor d reasons for 
screening failure, as applicable.
Every effort shoul d be made to ensure that protocol -required tes ts and procedures are 
completed as described.  However, it is anticipated that from time to time there may be 
circumstances outside the control of the investigator that may  make it unfeasible to perform 
the test.  In these cases, the investigator must take all steps necessary  to ensure the safet y and 
well-being of the participant
.  When a protocol -required test cannot be performed, th e 
investigato r will document the reason for the missed test and any corrective and preventi ve 
actions that he or she has take n to ensure that required processe s are adhered to as soon as 
possible.  The study  team must be informed of these incidents in a timely  manner.
For samples being collected and shipped, detailed collection, proc essing, stor age, and 
shipment instructions and contact information will be provi ded to the investigator site prior 
to initiation of the study .

PF-06882961
Protocol C3421005Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 49The total blood sampling volume for individual participants in this study is approximately 
295 mL.  The actual collection times of blood sampling may change.  Additional blood samples may be taken for safety assessments at times specified by Pfizer, provided the total volume taken during the study does not exceed 550 mL during any period of 60 consecutive days.
8.1. Efficacy Assessments
Efficacy assessments for this study include measurements of HbA1c, fasting plasma glucose, 
and body weight which are covered in detail in Section 8.2 .
8.1.1. Primary Efficacy Parameter: HbA1c
HbA1c is the primary efficacy parameter for this study.  See Section 8.2.6 covering clinical 
laboratory tests.
8.1.2. Secondary  Efficacy Parameters
See Section 8.2.6 (clinical laboratory assessments) for details regarding fasting plasma 
glucose. Participants achieving HbA1c <7% will be calculated based on HbA1c assessments as described in Section 8.2.6 .
See Section 8.2.2 for details regarding assessment of body weight.
8.2. Safety Assessments
Planned time points for all safety assessments are provided in the SoA.  Unscheduled clinical 
laboratory measurements may be obtained at any time during the study to assess any 
perceived safety concerns.
8.2.1. Physical Examinations
Physical examinations are performed as indicated in the SoA.  
Physical examinations may be conducted by a physician, trained physician’s assistant or 
nurse practitioner as acceptable and according to local regulation.  A complete physical examination will include, at a minimum, assessments of the head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, and gastrointestinal, musculoskeletal and neurological systems.  
Height will be measured at screening only.A limited physical examination is performed at the follow up visit and may be performed at 
non-specified visits if there are findings during the previous physical examination or 
new/open AEs, if appropriate and at investigator discretion.  The limited physical 
examination will be focused on general appearance, lungs, cardiovascular system, and participant reported symptoms.CCI
PF-068829 61
Protocol C3421005
Final Protocol Ame ndment 1 ,
19May 2020
PFIZER C ONFIDENTIAL
Page 50Investigators should pay  special a ttention to clinical signs related to previous serious 
illnesses.
8.2.2. Body Weight
Body weight will be measured in duplicate as indicated in the SoA. The second weigh t 
measurement sh ould be obtain ed at least 1 -2 minutes apart from thefirst measurement.
Weight will be recorded using a calibrated sc ale (with the same scale used if possible for the 
duration of the stu dy) reporting weight in eit her pounds ( lb) or kilograms (kg), and accuracy  
to the nearest 0.2 lb(or 0.1 kg); ie, the dev ice must be able to distinguish a difference 
between 150.4 lb(68.4 kg) versus 150.2 lb(68.3 kg).  The scale must be placed on a stabl e, 
flat surfa ce
.
Weight mea surement should be taken under the following conditions:
While participant is in a fasted s tate (see Section 5.3.1 );
After void of urine ;
After removal of shoes, bulky  layers of clothing and jackets so that only  light clothin g 
remains ;
While 
remaining still during the measurement .
8.2.3. Vital Signs
8.2.3.1. Blood P ressure and Pu lse Rate
In this stud y, assessment of vital signs [systolic BP, diastolic BP,and pulse rate (PR)] will 
occur at the nominal time points specified in the SoAper the following specifications:
At screenin g, thepartici pant’s arm cir cumference should be measured (eg, using a 
flexible anthropometric tape) at t he midpoint of the length of the upper arm and the 
appropriate cuff selected and used throughout the study .
Note: Participants with arm circumference g reater than t he largest cuf f size 
available at the site or >5 2cmare not eligible.   See Section 5.2.
BP and PRwill be measured viaan automated devi
ce using an oscillome tric method 
(not auscult ation).
Assess ment of BP and PR can be manual (rather than using a n automated device), 
only if an automate d device is not available; however when done manuall y PR 
must be measured in the brachial/radial artery  forat least 30 seconds.

PF-068829 61
Protocol C3421005
Final Protocol Ame ndment 1 ,
19May 2020
PFIZER C ONFIDENTIAL
Page 51Supine BPand PRwillbe measured w ith the participant’s arm supported at the level 
of the heart, and recorded to the nearest mm Hg, fol lowing a rest of at least 5 minutes.  
The a ssessment at Visit 3 (Day 1) will serve as the partic ipant’s baseline.  Triplicate 
assessments wil l
bemeasured at V3, V5, V7 and V9 with a brief inter val 
(eg,1-2minutes) betwee n successive triplicate assessments.
Same arm (preferabl y the dominant arm) will be used for BPand PRassessmen t
s
throughout the study, whenever possible.
Participants should be instructed not to speak during BPand PRmeasureme nts.
See Appendix 9for proposed chro nology  of procedures for nominal time point s when 
vital sig n assessments coinci de with other procedures. 
Additional colle ction times, or changes to collection times of BPand PRwill be permitte d, as 
necessary , to ensure 
appropriate collection of safety  data.
8.2.4. Electrocardiograms
Standard 12- Lead EC Gs should be collected at times sp ecified in the SoA section of this
protocol using an ECG machine that auto matically ca lculate s the heart rate and measur es PR, 
QT, and QTc Fintervals and QRS complex .Triplicate assessments will b e measured at V3 , 
V5, V7 and V9 witha brief interval (eg, 2 -5minutes) between successive tr iplicate 
assessments .  All scheduled ECG s should be perform ed after the participant has rested 
quietly  for at least 10 m inutes in a supine position. 
If a post dose QTc Finterval remains ≥30msecfrom the baseline andis a) >450 msec; or 
b) an absolute QTc Fvalue is ≥500 msecfor an y scheduled ECG for great er than 4 hours (or 
sooner, at the discretion of the investigator), or QTcF intervals get progressively  longer, the 
participant should undergo continuous ECG monitoring.  A cardiologist shou ld be consulted 
if QTc Fintervals do not return to less than the c riterion listed above after 8 hours of 
monitoring (or sooner, at the discretion of the investigator).
In some cases, it may  beappropr iate to repeat abnormal ECGs to rule out improper lead 
placement as contributing to the ECG abnormality .  It is important that leads beplaced in the 
same positions each time in order to achieve precise ECG recordings.  If a machine -read 
QTcFvalue is prol onged, as defined above, repeat measurements may  not be necessary  if a 
qualified medical provider’s interpretation determ ines that the QTc Fvalues are in the 
acceptable range.
ECG values of potential clinical concern arelisted inAppendix 7.
8.2.5. Management of Glycemic Control
Hypoglycemic adverse events ( HAE s )and fasting plasma glucose wil l be routinely  
monitored during pa rticipation in the study .

PF-068829 61
Protocol C3421005
Final Protocol Ame ndment 1 ,
19May 2020
PFIZER C ONFIDENTIAL
Page 52Based on this information, as well as review of the results reporte d by thecentral laboratory , 
an assessment of an y symptomatic a nd asymptomatic occurrence of hy po-or hyper-glycemia 
must be unde rtaken.
8.2.5.1. Home Glucose Monitoring
Toaide in management of their T2DM, all 
participants will be provided home 
glucose monitoring supplies including a Sponsor -provided glucometer, instructions 
on the use of the glucometer and accompan ying supplies.
Home glucose monitoring logs will be provide d to participants for completion at 
home and brought to each outpatient visit to the site alo ng with the glucometers.  
Investigators must review the home gl ucose monitoring logs completed by  the 
participants and the readin gs stored in the glucometer device at each visit to the site 
after the placebo run -in visit (V2).
Participants must perform hom e glucos e monitoring at least 3 times weekly  following 
at least an 8-(preferably  10- ) hour fast (except water).  However, the inv estigator may  
recommend more frequ ent home glucose monitoring if needed.
Less frequent glucose monitoring will NOT be considere d a prot ocol deviation unless 
the participant fails to monitor his/her glucose for 3 or more consecutive days.
If the participant experiences s ymptoms of hy pogly cemia, home glucose monitoring 
should be performed, and these sy mptoms, along with the glucomet er measu rement, 
should be captured on the home glucose monitori ng log.
If the participant uses his/her own glucometer, and not on e provided b y the Sponsor, a 
protocol deviation will NOT be recorded provided the investigator is still able to 
monitor the par ticipant ’s daily  glucose values according to the criteria state d above.
8.2.5.2. Management of Hypoglycemia
Any episode of hy poglycemia mu st be captured on the Adverse Event CRF with specific 
details captured on the Hypogly cemia Adverse Event Form CRF.  For the def inition of a 
hypoglycemic episode and severit y categorization s ee Section 8.2.5.2.1 below.
Participants noted to have a fasting glucose value (during home glucose monitoring) meeting 
the de finition of hy poglycemia must be instructed to repeat the measur ement the next day  
(following at least an 8 (preferabl y10) hour fast, e xcept water).  If the second measurement 
also meets the below definition, participants must be asked to return to the si te withi n 1 to 
3days (following at least an 8 (preferabl y10) h our fa st, except water) and have blood 
collected and sent to the central laboratory  for analy sis of fasting plasma glucose.

PF-068829 61
Protocol C3421005
Final Protocol Ame ndment 1 ,
19May 2020
PFIZER C ONFIDENTIAL
Page 538.2.5.2.1. Definition and Severity of Categorization of Hypoglycemic Adverse Ev ent 
(HAE )
Based on review of the participant completed home gluc ose monito ring log at each site visit, 
as well as results reported by  the central laboratory , the i nvestigator must assess the glucose 
values as well as an y symptoms documented.
HAE is defined as oneof the following :15
1.Asymptomatic hypoglycemia: An event not accompanied by  typical s ymptoms of 
HAE but a blood glucose value of <70 mg/dL (3.9 mmol/L) using either glucometer 
(fingerstick blood gluco se) or sponsor -identified central laboratory (plasma glucose );
2.Documented s ymptomatic hypoglycemia: 
An event during wh ich ty pical sy mptoms 
of HAE are accompanied with a glucose value of <70 mg/dL (3.9 mmol/L) using 
glucometer (or sponsor -identified central la boratory ) and the clinical picture includes 
prompt resolution with food inta ke, subcutaneous glucagon, or intraveno us (IV)
glucose; 
3.Proba ble symptomatic hypoglyce mia: An event during which 
symptoms of HAE 
are not accompanied b y a glucose determinat ion but was presumabl y caused by a 
blood glucose concentration of <70 mg/dL (3. 9mmol/L), and the clinical picture
includes prompt resolution wit h food intake, subcutaneous glucagon, or IVglucose.
Each episode of HAE must be categorized with respect to severit y.  In order to characterize 
the event as severe, all three (3) criteria b elow must be met:
1.The participant w as unable to treat him/herself.   Neurologic impa irment, and not the 
age of the participant, is the explanation for wh y the participant co uld not trea t 
him/herself and required the assistance of another person.
2.The partici pant exhibited at least one of the following neurological s ymptoms :
Memory  loss;
Confusion;
Uncontrolled behavior ;
Irrational behavior ;
Unusual difficulty  in awakening ;
Suspected seizu
re;
Seizure ;

PF-068829 61
Protocol C3421005
Final Protocol Ame ndment 1 ,
19May 2020
PFIZER C ONFIDENTIAL
Page 54Loss of consciousness .
3.Either:
If blood glucose was measure d and was ≤54mg/dL (2.7 mmol/L) using 
glucometer (or central laboratory ); or
If blood glucose was not measured, the clinical manifestations were reversed by  
oral carboh ydrates, subcutaneous glucagon, or intravenous glucose.
Events that do not meet all the criteria above for severe HAE are characterized as mild or 
moderate in severity .
Any episode of HAE must be captured on the HAE CRF.
8.2.5.3. Management of Hyperglycem ia
Hypergl ycemia is defined as the following:
Fasting glucose ≥270 mg/dL  (15.0 mmol/L) using glucome ter (or central laboratory ). 
After randomization, participants noted to have a fasting glucose value (during home glucose 
monitoring) meeting the above definition of h ypergl ycemia must be instructed to repeat the 
measurement the next day  (following at least an 8 (preferabl y10) hour fast, except water).  If 
the second measurement also meets the above definition, participants must be asked to return 
to the site a day  later (following at least an 8 (preferably 10) hour fast, except water) and 
have blood collected f or fasting plasma glucose (and shipped to the central laboratory  for 
analysis).
The investigator should determine if the participant collected the samples after an adequate 
fasting period; and if the part icipant is following recommended dieta ry guidelines.   Proper 
dietary  and collected procedures should be reinforced with the participant.
If the results from the central laboratory  confirm the readings using glucometer, the 
participant should receive glycemic 
rescue medication at the discretion of the invest igator 
(see Section 6.5.5 ).
8.2.6. Clinical Laboratory Assessments
See Appendix 2 for the list of clinical safet y laboratory  tests to be performe d and the SoA for 
the timing and frequency.
The investigator must review the laboratory  report, document this review, and record any  
clinically  relevant changes occurring during the study  in th e AE section of the CRF. 
Clinically  significant abn ormal laboratory  findings are those which are not associated with 
the underl ying disease, unless judged by  the investigator to be more severe than expected for 
the participant's condition.

PF-068829 61
Protocol C3421005
Final Protocol Ame ndment 1 ,
19May 2020
PFIZER C ONFIDENTIAL
Page 55All laboratory  tests with values considered clinicall y significantl y abnormal during 
participation in the study  or within 28 to 35 daysafter the last dose of stud y intervention 
should be repeated until the values return to normal or baseline or are no longer considered 
clinically  significant b y the investig ator or medica l monitor.
If such values do not return to normal/baseline within a period of time judged reasonable by  
the investigator, the etiology  should be identified and the sponsor notified.
All protocol -required laboratory  assessments, as defined in Appendix 2 , must be conducted 
in accordance with the laboratory  manual and the SoA.
If laboratory  values from non- protocol -specified laboratory  assess ments performed at the 
institution’s l ocal laborator y require a change in participant management or are considered 
clinically  significant b y the investigator (eg, SAE or AE or dose modification), then the 
results must be recorded in the CRF.
8.2.7. Pregnancy Test ing 
Pregnancy  tests will be both urine andserum te sts, andmust have a sensitivity  of at least 
25mIU/mL.  Pregnancy  tests will be performed in all females at the times listed in the SoA.  
Following a negative pregnancy  test result at screening, appropriate contracep tion must be 
commenced and a second negative pregnancy  test result will be required at the baseline visit 
prior the participant ’sreceiving the IP.  Pregnancy tests will also be done whenever 
1menstrual cy cle is misse d during the active treatment period (or when potent ial pregnancy  
is otherwise suspected) and at the end of the stud y.  Pregnancy tests may also be repeated if 
requested b y institutional review boards (IRBs)/ethics committees (ECs) or if required b y 
local regulations.  
8.3.Adverse Events and Seri ous Adverse Events
The definitions of an AE and an SAE can be found in Appendix 3 .
AEswill be reported b y the participant (or, when appropriate, b y a caregiver, surrogate, or 
the participant's legall y authorized r epresentative) .
The investigator and an y qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible to pursue 
and obtain adequat e information both to determine the ou tcome and to a ssess whether it 
meets the criteria for classification as an SAE or that caused the participant to discontinue the 
study  intervention (see Section 7). 
In addition, the investigator may be request ed by Pfizer Safet y to obtain specific follow -
up 
information in an expedited fashion.

PF-068829 61
Protocol C3421005
Final Protocol Ame ndment 1 ,
19May 2020
PFIZER C ONFIDENTIAL
Page 568.3.1. Time Period and Frequency for C ollecting AE and SAE Information
The time period for actively  eliciting and collecting AEs and SAEs (“active collection 
perio d”) for each participant begins from the time the participant provides informed consent, 
which is obtained before the participant ’s participation in the study  (ie, before undergoing 
any study -related procedure and/or r eceiving IP), through and including a minimum of 
28calendar day s, except as indicated below, after the last administration of the IP.
For participant s who are screen failures, the active collection period ends when screen failure 
status is determined.
Follow -up by  the investigator continues throu ghout and after the active collection period and 
until the event or its sequelae resolve or stabilize at a level acceptable to the investigator, and 
Pfizer concurs with that assessment.
Investigators are not obligated to activel y seek AE sor SAE safter conclusion of the study  
participation .  However, if the investigator learns of any  SAE, including a death, at an y time 
after a participant has been discharged from the study , and he/she considers the event to be 
reasonabl y related to the study  intervention or study  participation, the investigator must 
promptly  notify  the sponsor.
8.3.1.1.
Reporting SAEs to Pfizer Safety
All SAEs occurring in a participant during the active collection period are reported to Pfizer 
Safety  on the CT SAE Report Form immediatel y and under no circumst ance should this 
exceed 24 hours, as indicated in Appendix 3 . The investigator will submit any  updated SAE 
data to the sponsor within 24 hours of it being available.
SAEs occurring in a participant after the activ e collection period has ende d are reported to 
Pfizer Safety  if the investigator becomes aware of them; at a minimum, all SAEs that the 
investigator believes have at least a reasonable possibility of being related to IP must be 
reported to Pfizer Safet y.
8.3.1.2. Recording Nonserious AEs and S AEs on the CRF
During the active collection period, both nonserious AEs and SAEs are recorded on the AE 
section of the CRF.
8.3.2. Method of Detecting AEs and SAEs
The method of recording, evaluating, and assessing causality  of AE sandSAE sand the 
procedures for completing and tr ansmitting SAE reports are provided in Appendix 3 .
Care will be taken not to introduce bias when detecting AEs and/or SAEs.   Open -ended and 
nonleading verbal questioning of the participant is the preferred method t o inquire about 
AEoccurrences.

PF-068829 61
Protocol C3421005
Final Protocol Ame ndment 1 ,
19May 2020
PFIZER C ONFIDENTIAL
Page 578.3.3. Follow -up of AEs and SAEs
After the initial AE/SAE report, the investigator is required to proactivel y follow each 
participant at subsequent visits/contacts. For each event, the investi gator must pursue an d 
obtain adequate information until resolution, stabilization, the event is otherwise explained, 
or the participant is lost to follow- up (as defined in Section 7.3).
Ingeneral , follow -up informat ion will include a description of the event in sufficient detail to 
allow for a complete medical assessment of the case and independent determination of 
possible causality .  An y information relevant to the event, such as concomi
tant med ications 
and illnesses, must be provid ed.  In the case of a participant death, a summary of available 
autopsy  findings must be submitted as soon as possible to Pfizer Safety . 
Further information on follow -up procedures is given in Appendix 3 .
8.3.4. Regulatory Reporting Requirements for SAEs
Prompt notification by  the investigator to the sponsor of a n SAE is essential so that legal 
obligations and ethical responsibilities towards the safet y of participants and the safet y of a 
study  intervent ion under clinical investigation are met.
The sponsor has a legal responsibility  to notify  both the local regulatory  authority  and other 
regulatory  agencies about the safet y of a stud y intervention under clinical investigation. The 
sponsor will comply  with country -specific regulatory  requirements relating to safet y 
reporting to the regulatory  authorit y, IRBs/ECs, and investigators.
Investigator safety  reports must be prepared for suspected unexpected serious adverse 
reactions (S USAR s) according to local re gulatory  requireme nts and sponsor policy  and 
forwarded to investigators as necessary .
An investigator who receives an investigator safety report describing a nSAE or other 
specific safet y information (eg, summary or listing of SAEs) fro m the sponsor will r eview 
and then fil e it along with the i nvestigator’s brochure and will notify  the IRB/EC, if 
appropriate according to local requirements.
8.3.5. Exposure During Pregnancy or Breastfeeding, and Occupational Exposure
Exposure to the inve stigatio nal product under st udy during pregnan cy or breastfeeding and 
occupational exposure are reportable to Pfizer Safety  within 24 hours of investigator 
awareness.
8.3.5.1. Exposure During Pregnancy
Details of all pregnancies in female participants will be colle cted aft er the start of stud y 
intervention and until 28calendars day s after the last administration of IP.  
If a pregnancy is reported, the investigator should inform the sponsor within 24 hours of 
learning of the pregnancy and should follow the procedures outli ned in Appendix 4 .

PF-068829 61
Protocol C3421005
Final Protocol Ame ndment 1 ,
19May 2020
PFIZER C ONFIDENTIAL
Page 58Abnormal pregnancy  outcomes (eg, spontaneous abortion, fetal death, stillbirth, congenital 
anomalies, ectopic pregnancy ) are considered SAEs.
8.3.5.2. Exposure During Breastfeeding
Scenarios of expo sure during breastfe eding must be reported, irrespective of the presence of 
an associated SAE, to Pfizer Safet y within 24 hours of the investigator’s awareness, using the 
CT SAE Report Form.  An exposure during breastfeeding report is not created w hen a Pf izer 
drug specifical ly approved for us e in breastfeeding women (eg, vitamins) is administered in 
accord with authorized use.  However, if the infant experiences an SAE associated with such 
a drug’s administration, the SAE is reported together with the expo sure during breastfe eding.
8.3.5.3. Occupationa l Exposure
An occupational exposure occurs when, during the performance of job duties, a person 
(whether a healthcare professional or otherwise) gets in unplanned direct contact with the 
product, which may  or m ay not l ead to the occurrenc e of an AE.
An occ upational exposure is reported to Pfizer Safety within 24 hours of the investigator’s 
awareness, using the CT SAE Report Form, regardless of whether there is an associated 
SAE.  Since the information does not p ertain t o a participant enrolled in the study ,the 
information is not recorded on a CRF; however, a copy  of the completed CT SAE Report 
Form is maintained in the investigator site file .
8.3.6. Medication Errors
Medication errors may  result from the administration or cons umption of the IPbythe wrong 
partici pant, or at the wrong time, or at the wrong dosage strength.
Exposures to the IPunder study  may  occur in clinical trial settings, such as medication 
errors.
Safety Event Recorded on the CRF Reported on the CT SAE Rep ort 
Form to Pfizer S afety Within 
24Hours of Awareness
Medication errors All (regardless of whether 
associated with an AE)Only  if associated with an SAE
Medication errors include:
Medication errors involving participant exposure to the IP;
Potential me dication errors or uses outside of what is foreseen in the protocol that do 
or do not involve the study participant .

PF-06882961
Protocol C3421005Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 669.4.1. Efficacy Analyses
Endpoint Statistical Analysis Methods
Primary: Change 
from baseline in HbA1c at Week 16.A MMRM analysis of the change from baseline in HbA1c through
Week 16 will be used to estimate the treatment effect related to the primary Estimand 1A.
The MMRM will include treatment, time, strata (metformin vs. diet 
and exercise alone) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect.  An unstructured correlation matrix will be used, and the Kenward-Roger approximation will be used for estimating degrees of freedom for the model parameters.
The MMRM model will be fitted to change from baseline to 
Weeks 2, 4, 6, 8, 12 and 16 from the Estimand Set 1A. 
Missing values will be imputed as part of the MMRM model 
assumptions.
No adjustments will be made for multiplicity.
Secondary: 
Response as defined by anHbA1c <7% at Week 16.A logistic regression analysis of participants who reached a HbA1c 
goal of <7% at Week 16 and those that didn’t will be used to estimate the treatment effect related to the secondary estimand 2.
The logistic regression model will include a term for treatment, 
strata (metformin vs. diet and exercise alone), and baseline HbA1cwill be included as a covariate.  
This model will be fitted to the Week 16 timepoint only from the 
Estimand Set 1A.  No adjustments will be made for multiplicity.
Secondary: Change from baseline in fasting plasma glucose through and at Weeks 2, 4, 6, 8, 12 and 16.Changes from baseline in fasting plasma glucose at Weeks 2, 4, 6, 8,
12 and 16 will be analyzed using a similar MMRM model to thatused for the primary endpoint.  Baseline fasting plasma glucose will be included as a covariate in the model, rather than baseline HbA1c.  No adjustments will be made for multiplicity.
This analysis will be applied to the Estimand Set 1A to estimate the 
treatment effect related to Estimand 3.
Secondary: Change from baseline in body weight at Weeks 2, 4, 6, 8, 12 and 16.Changes from baseline in body weight will be analyzed using a 
similar MMRM model to that used for the primary endpoint.  Baseline body weight will be included as a covariate in the model, rather than baseline HbA1c. No adjustments will be made for multiplicity.
This analysis will be applied to the Estimand Set 1A to estimate the
treatment effect related to Estimand 4.
CCI
PF-068829 61
Protocol C3421005
Final Protocol Ame ndment 1 ,
19May 2020
PFIZER C ONFIDENTIAL
Page 6910.SUPPORTING DOCUM ENTATION AND OPER ATIONAL CONSIDERA TION S
10.1. Appendix 1: Regulatory, Ethical, and Study Ov ersight Considerations
10.1.1. Regul atory and Ethica l Consideratio ns
This study  will be conducted in accordance with the protocol and with the following:
Consensus ethical pr incip les derived from internat ional gui delines including the 
Declaration of Helsinki and C
ouncil for International Org anizations of Me dical
Sciences (CIOMS) International Ethical Guidelines ;
Applicable International Counc il for Harmonisation (I CH) Good Cli nical Practice 
(GCP) guideline s;
Applic able laws and regulations , including applicable privacy  laws .
The protocol, pro tocol amendments, I CD, investi gator’s brochure ( I B), and other relevant 
documents (eg, advertisements) must be reviewed and approved by  the sponsor and 
submitte dto an IRB/EC by theinvestigator and reviewed and approved b y the IRB/EC 
before the study  is initiated.
Any amendments to the protocol will require IRB/EC approval before implementation of 
changes made to the study  design, except fo r cha nges necessary  toelimina te an immedia te
hazard to study  participants.
The investigat or will be responsible for the following:
Providi ng writte n summaries of the status of the study  to the IRB/EC annually  or 
more fre quently  in accordance with the requ ireme nts, policies, an dproced ures 
established by the IRB/EC ;
Notify ing the IRB/EC of SAEs or other significant safet yfindings as req uire
dby 
IRB/EC procedures ;
Providing oversight of the conduct of the stud y at the site and adherence to 
requirements of 21 Cod e of Federal Regu lations ( CFR ), ICH gu idelines, the I RB/EC, 
European regulation 536/2 014 for clinical studies (if applicable), an d all other 
applicable local regulations .
10.1.1.1. Reporting of Safety Issues and Serious Brea ches of the Protocol or ICH GCP
In the eve nt of any  prohibi tion or restricti on imposed (ie, clinical hold) b y an applicable 
regulatory  authorit y in any are a of the world, or if the inve stigator is aware of any  new 
information that might influence the evaluat ion of the benefits and risks of th e investigational 
product, Pfi zer shoul d be i nformed immediately . 

PF-068829 61
Protocol C3421005
Final Protocol Ame ndment 1 ,
19May 2020
PFIZER C ONFIDENTIAL
Page 70In addition, the investigator will inform Pfizer im mediately  of any urgent safet ymeasures 
taken b y the investigator to protect the study participant
s aga inst any  immediate hazard, and 
of any serious breaches of this pr otocol or of ICH GCP that the investigator becomes aware 
of.
10.1.2. Financial Disclosure
Invest igators and sub inv estigators will provide the sponsor with sufficient, accurate financial 
information as requested to allow the sponsor t o submit complete and accurate financia l 
certification or disclosure statements to the app ropriate regulatory  authorit ies. Investigat ors
are responsible for providing information on financial interests during the course of the stud y 
and for 1 yearafter c omple tion of the study .
10.1.3. Inform ed Consen t Process
The investigator or his/her representative will explain the nature of the study  to th e 
participant or his/her legally  authorized representative and answer all questions reg arding the 
study .
Participants must be informed that their partic ipation is volu ntary .Participants or their 
legally  authori zed representative defined a s legal guardian willbe requi red to sign a 
statement of informed consent that meets the requirements of 21 CFR 50, local regulations, 
ICH guidelines, Health Ins urance Portability  and Accountability  Act (HI PAA) requirements, 
where applicable, and the I RB/E C or study  cente r.
The investi gator must ensure that each study  participant or his or her legally  autho rized 
representative is fully  infor med a bout the nature a nd objec tives of the study, the sharing of 
data related to the study ,and possible risks associa ted with participat ion, includ ing the risks 
associated with the processing of the participant
’s persona l data. 
The participant must be in forme d that his/her per sonal s tudy-related da ta will be used by  the 
sponsor in accordance with local data protection l aw. The level o f disclosure m ust also be 
explained to the participant.
The participant must be informe d that his/her medical records may  be ex amined by  Clinica l
Qualit y Assuran ce auditors or other authorized personnel appointed by the sponsor, by  
appropri ate IRB/EC membe rs,and by  ins
pectors from regulatory  authorities.
The investigator further must ensure that each study  participant or his or her legally 
author ized rep
resentative i s fully  informed about his or her right to acce ss and correct his or 
her pe rsonal data and to withdraw co nsent for the processing of his or her personal data.
The medical record must include a statement that written informed consent wa sobtain ed 
before theparticipant was enrolled in the study  and the date the written consent was obtained.
The authorized per son obtaining the informed consent must also sign the IC D .

PF-068829 61
Protocol C3421005
Final Protocol Ame ndment 1 ,
19May 2020
PFIZER C ONFIDENTIAL
Page 72In all cases, stud y results are reported b y Pfizer in an objective, accurate, bal anced , and 
complete ma nner and are repo rtedregardless of the outcome of the study  or the country  in 
which the study  was conducted.
ww
w.clinicaltria ls.gov
Pfizer posts clinical trial US Basic Results on www.clinicaltrials .gov for Pfizer -sponsored 
intervent ional studies (conduct ed in pa tients) t hat evaluate the safet y and/or efficacy of a 
produc t, regardless of the geograp hical location i n whi ch the st udy is conducted.  US Basic 
Results are generall y submitted for posting w ithin 1 y ear of the primary  complet ion d ate 
(PCD) for stu
dies in adult pop ulations or within 6 months of the PCD for studies in pediatric 
populations.
PCD is defined as the date that the final participant was examined or received an intervention 
for the pu
rposes of final collection of data for the primary  outcom e, wheth er the cl inical
study  concluded according to the prespecified protocol or was terminated.
EudraCT
Pfizer posts Europea n Union (EU) Basic Results on EudraCT for all Pfizer -sponsored 
interventi onal studies that are in scope of E U requirements.  EU Ba sic Resu lts are s ubmi tted 
for posting within 1 year of the PCD for s tudies in adult populations or within 6 mont hs of
the PCD for studies in pediatric populations.
www.pfizer.com
Pfizer posts public disclosure s ynopses (CSR synopses i n whi ch an y data that c ould be used 
to identify  individual participants have been removed) on www.pfizer.com for 
Pfize r-sponsored inte rventional stu dies at the same time the US Basic Results document is 
posted to 
www.clin icaltrials.gov .
Documents within ma rketing authorization packages /submissi ons
Pfizer complies with the European Union Policy  0070, the proactive publication of clinical 
data to the Eu ropean Medicines Agency (EMA) website.  Clinical data, under Phase 1 of t his 
policy , includes clinical overviews, clinical summari es, CSRs, and appendices containing the 
protocol and protocol amendm ents, sample CRFs, and stati stical methods. Clinical data , 
under Phase 2 of this policy , includes the publishing of individual par ticipant data.  
Policy 0070 applies to new marketing auth orizatio n applica tions submitted via the 
centralized procedure since 01January 2015 and applica tions for line e xtensions and for new 
indications submitted via the centralized procedure since 01 July 2015.

PF-068829 61
Protocol C3421005
Final Protocol Ame ndment 1 ,
19May 2020
PFIZER C ONFIDENTIAL
Page 73Data Sharing
Pfizer provides researchers secure ac cess to patient-l evel data or full CSRs for the purposes 
of “bona -fide scientific research” that contribute to the scientific understanding of the 
disease, target, or compound class. Pfizer will mak e available data from these trials 
24months after study  completi on.  Pati ent-level data will be anon ymized in accordance with 
applicable privacy  laws an d regulations.  CSRs will have personall y identifiable information 
redacted.
Data requests are consider ed from qualified researchers with the a ppropriate compet encies t o 
perform theproposed analy ses. Research teams must include a biostatistician. Data w ill not 
be provi dedto applica nts with significant conflicts of interest, including individuals 
request ing access for commercial/competiti ve or legal purposes.
10.1.6. D ata Quality Assu rance
All participant data relating to the stud y will be recorded on printed or electronic CRF unles s 
transmi tted to the sponsor or designee electronically  (eg, laboratory  data). The investigator is 
responsible for v erify ing that data ent ries are accurate andcorrect by  physically  or 
electronically  signin g the CRF.
The investigator must maintain ac curate documen tation (source data) that supports the 
information entered in the CRF.
The investigator must ensure that the CRFs are securel y sto red at t he study site in encry pted 
electronic and/or paper form and are password protected or se cured in a locke d room to 
prevent access b
y unauthorized third parties.
The investigator must permit st udy-related monitoring, audits, IRB /EC r eview, and 
regula tory agency inspe ctionsand provide direct access to source data doc uments.   This 
verification m ay also occur af terstudy comp letion.  I t is important that the investigator(s) 
and their relevant pers onnel are available during the moni torin
g visits and possi ble audits or 
inspections and that sufficient time is devoted to th e process.
Monitoring details describing str ategy(eg, ris k-based initiatives in operations and quality  
such as risk management and mitigation strategies and analytical risk-based monitori ng), 
methods, res pons ibilities ,
and requirements, including handling of noncompliance issues and
monitoring tech niques (centra l, remote, or on -site monitoring) ,are provided in the 
monitoring 
plan.
The sponsor or designee is responsible fo r the data manage ment of this stud y, inc luding 
quality  checking of the data.

PF-068829 61
Protocol C3421005
Final Protocol Ame ndment 1 ,
19May 2020
PFIZER C ONFIDENTIAL
Page 74Study  monitors will perform ongoing source data verific ation to confirm that data entered 
into the CRF by  authorized site personnel are acc urate, complete, and verifiable fro m sou
rce 
documents; that the s afety  and rights of participants are being protected; and th at the study  is 
being conduc ted in accordanc e wit h the cur rently  approved protocol and any  other study  
agreements, I CH GCP, and all applicable regulatory  requirements.
Records and document s, including sign ed IC Ds, pertaining to the conduct of this study  must 
be retained b y the invest igator for 15 yearsafter stud y completion unless local regulations or 
institutional policies require a longer retention period. No recor ds ma y be destroyed du ring 
theretention pe riod without the written approval of the sponsor. No records may  be 
transf erred to another location or part y without written notification to the sponsor. The 
investigator must ensure that the records continue to be stored securel y foraslong as they are
maintained.
When participant data are to be de leted, the investigator will ensure that all copies of suc h 
data are promptly  and irrevocabl y deleted from all systems.
The investi gator(s) will notify thesponsor or its agents immediatel yof any regulato ry 
i
nspection notification in relation to the study .  Furthermore, the investigator will cooper ate
with the sponsor or its agents to prepare the investigator site for the inspection and will allow 
the sponsor or its a gent, whenever feasibl e, to be present duringthe inspection.  The 
investigator site and investigator will promptly  resolve any  discre pancies that a re identified 
between the stud y data and the participant's medical record s.  The investigator will promptly  
provi de copies of the i nspecti on findings t o the sponsor or its agent.  Before response 
submission to the regulatory  authorities, the inv e stigator w ill provide the sponsor or its 
agents with an opportunity to review and c omment on responses to an y such fin dings .
10.1.7. Source Document s
Source document s provide evidence for the existence of the partici pant and substantiate the 
integrit y of the d atacollected. Source document s are filed at the investigator site.
Data reported on t he CRF or entered in the electronic CRF ( eCRF )that are t ranscrib ed from 
source documents must be consistent with the source documents or the discrepanci
es must be 
expla ined.The inv estigator may  need to request previous medical records or transfer 
record s, depending on the study . Also, c urrent medical records must be availabl e.
Definition of what constitutes source data can b e found in the study  monitor ing plan (SMP) .
10.1.8. Stud
yand Site Closure
The sponsor designee reserves the right to close the study  site or terminate the study  at any  
time for any reason at the sole dis cretion of the sponsor. Study  sites will be closed upon 
study completion. A study  site is considered c losedwhen all required documents and study  
supplies have been collected and a stud y-site closure visit has been performed.

PF-068829 61
Protocol C3421005
Final Protocol Ame ndment 1 ,
19May 2020
PFIZER C ONFIDENTIAL
Page 75Theinvestigator may initiat e study -site closure at any  time upon notification to the contract 
research organization ( CRO )if reques tedto do so b y the responsible IRB/EC or if such 
termination is required to protect th e health of study  participants.
Reasons for the earl y clo sure of a stud y site by the sponsor may  include but are not limited 
to:
Failure of the investiga tor to comply  with the protocol, the requirements of the 
IRB/EC or local health authorities, the sponso
r's procedures, or GCP guidelines;
Inadequate recruitment of participants by theinvestigator ;
Discontinuation of further stu dy intervention development .
Study  terminati on is also pro vided for in the clinical study  agreement.  If there is any  conflict 
betw een the contract and this protocol ,the contract will cont rol as to termination rights.
10.1.9. Publication Policy
The results of thi s study  may  be published or presented at sci entific meetin gs by the 
investigator after publication of the overall study  results or 1year after end of the study  (or 
study termination), whic hever c omes firs t. 
The investigator agrees to refer to the primary publication in any  subseque nt publications 
suchas second ary manuscripts and submit s all manuscripts or abstracts to the sponsor 
30days before submission. This all ows t he sponsor to prot ect pro prietary  information and to 
provide comments and the investi gator will, on request, remo ve an y previousl y undisclosed 
confidential information before disclosure, except for an y stud y
- or Pfiz er 
intervention -related information necessary  forthe app ropriate scientif ic pre sentation or 
understanding of the study  resul ts.
For all publications rel ating to the stu dy, the invest igator will compl y with recognized ethical 
standards concerning publicati ons and authorship, including those esta blished by  the 
Internatio nal Commi tteeof Medical Journal Editors.
The sponsor will c omply  with the requirements for publication of t
he over allstudy  results 
covering all i nvestigator sites.   In accordance with stand ard editorial and ethical practice, the 
sponsor will supp ort publication o f mu lticenter studies only  in their entirety and not as 
individual site data.
  In this case, a coordinating i nvestigator will be designated b y mutual 
agreement.
Authorship of publica tions for the overall study  results willbe determined by mutual 
agreement andin line with I nternational Committee of Medica l Journal Editors authorship
requirements. 
If publication is addressed in the clinical study  agreement, the publication policy  setout in 
this section will not apply .

PF-068829 61
Protocol C3421005
Final Protocol Ame ndment 1 ,
19May 2020
PFIZER C ONFIDENTIAL
Page 7610.1.10. Sponsor’s Qualified Medical Personnel
Thec
ontact information for the sponsor's appropri ately  qualified medical pers onnel for the 
studyis documented in the study  contact list located in the study  team on demand (SToD) 
system.  
To facilitate access to a pprop riatel y qualified medical personne l onstudy-related medical 
questions or problems, participant s are provided wit h a contact card .  The contact card 
contains, at a minimum, protocol and investigational product identi fiers, participant numbers, 
contact info
rmation for the i nvestiga tor site, andcontact details for a contact center in the 
event that the investigator si te staff cannot be r
eached to provide advice on a medical 
question or problem originating from another healthcare professional not involve d in the 
participant ’spartici pation in thestudy.  The contact number can also be used by investigator 
staff if they  are seeking advi ce onmedical questions or problems; however, it should be used 
only in the event that the established communication pathw ays between the invest igator s ite 
and t he study team are not available.  It is therefore i
ntended to augment, but not replace, the 
established communication pathway s between the investigator site and the study  team for 
advice on medical questions or proble ms th at may arise duri ng the s tudy.  The co ntact 
number is not intended for use b y the participant directly , and if a 
participant calls that 
number, he or she will be directed back to the investigator site.

PF-068829 61
Protocol C3421005
Final Protocol Ame ndment 1 ,
19May 2020
PFIZER C ONFIDENTIAL
Page 7710.2. Appendix 2: Cl inical Laboratory Tests
The followi ng la boratory tests wi ll be pe rformed a t time s defined in the SoA section of this 
protocol.  Additional labor atory results may  be reported on these samples as a result of the 
method of anal ysis or the ty pe of anal yzer used b y the c linical laboratory ; oras deri ved from 
calculated values.  These additional tests would no t require additional collect ion of blood.  
Unscheduled cli nical laboratory  measurements may  be obtained at any  time during the stud y 
to assess an y perceived safet y concerns.

PF-06882961
Protocol C3421005Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 79After randomization, the sponsor study team and site will be blinded to HbA1c, fasting 
plasma glucose, measured by the central laboratory, unless the fasting plasma glucose meets the criterion for hypo-or hyper-glycemia as listed in Section 8.2.5.2 and 8.2.5.3 .CCI
PF-068829 61
Protocol C3421005
Final Protocol Ame ndment 1 ,
19May 2020
PFIZER C ONFIDENTIAL
Page 83events : (1) SAEs; (2) nons eriou s adverse events (AEs); and (3) exposure to the 
investigational product under study  during pregnancy  or br eastfeeding, and occupational 
expos ure. 
It should be not ed that the CT SA E Report Form for reporting o f SAE information is n ot 
the same as the A E pag e of the C RF.  W hen the same data are collec ted, the forms must be 
completed in a consistent manner.  AEs should be recorded using concise me dical
termi nology  and the same AE term should be used on both the CR F and the CT SAE 
Repor t Form for reporting of SAE informa tion.
Safety Event Recorded on the CRF Reported on the CT SAE 
Report Form to Pfizer 
Safety Withi n 24 Hours of 
Awareness
SAE All All
Nonserio us AE All None
Exposure to the 
investigational product 
under study  during 
pregnancy  or 
breastfeedi ng, a
nd 
occupat ional exposureAll AEs/SAEs associated 
with exposure during 
pregnancy  or breastfeeding
Occupational exposure is 
notrecor dedAll (and ex posureduring 
pregnancy  [EDP ]
supplemental form for 
EDP)  
Note: I nclude all SAEs 
associated with exposure 
during pregnancy  or 
breastf eeding.  Include all 
AEs/SAEs associated with 
occupational exposure
When an AE/SAE occurs, it is the respons ibility  of the inve stigator to review a ll 
documentation (eg, hospita l progress notes, labo ratory  reports, and diagnost ic 
repor ts) re lated to the event.
The investigator will then record all relevant AE/SAE information in the CRF.
It is notacceptable for the in vestiga tor to sendphotocopies of the participant’s 
medical rec ords to Pfizer Safety  in lieu of completio n of theCT SAE Repor t
Form /AE/SAE CRF page.
Ther e may  be instances when copies of medical records for certain cases are 
requested b y Pfizer Safet y. In this case, a ll participant ident ifiers, with the 
exception of the participant numbe r, will be redacted on the c opies of the medical 
records before submi ssion to 
Pfizer Safety .
The investigator will attempt to estab lish a diagnosis of the event based on signs, 
symptoms , and/or other clini cal information. Whenever po ssible, the diagnosis 

PF-068829 61
Protocol C3421005
Final Protocol Ame ndment 1 ,
19May 2020
PFIZER C ONFIDENTIAL
Page 8710.4. Appendix 4: Contraceptive Guidance and Collection of Pregnancy Information
10.4.1. Male Part icipa nt Repr oductive I nclusion Criteria
No contraception methods are required for male par ticipants in this st udy, as the calc ulate d
safet y margin is ≥100- foldbetween the estimated maternal exposure due to seminal transfer 
and the NOAEL for serious manifestati ons of 
development al toxicity  in nonclinical studies. 
10.4.2. Female Par ticipant Reproductive Inclusion Criteria
A female partic ipant is eligible to par ticipate if she is not pregnant or breastfeeding, and at 
least 1 of the following conditions applies:
Is not a woman of child bearing potential ( WOCBP )(see definitions below in 
Section 10.4.3 ).
OR
Is a WOCBP and using a 
contraceptive method that is highly effective (with a failure 
rate of <1% per year), preferabl y with low user dependency , as described below
duringthe intervention period and for at least 28daysafter the last dose of study  
interventi on,which corresponds to the time needed to eliminate any  reproductive 
safet y risk of the study  intervention(s) . The investigator should eva luate t he 
effectiveness of the contraceptive method in relationsh ip to the first dose of study  
interevention. 
Is a WOCBP and using acontraceptive m ethod that is highly  effective (with a failure 
rate of <1% per year), with high usere depen
dency, as described bel ow during t he 
intervention period and for at leas t 28days after the last dose of study  intervention, 
which correspond s to th etime needed to elimina te any  reproductive sa fety risk of the 
study intervention(s).  In addition, a second effective metho d of c ontraception , as 
described below, must be used.  The invest igator should evaluate the effectiveness of
the contraceptive metho d in relationsh ip to the first dose of study  inter vention.
The investigator is responsible for r eview of medical history , menstrua lhistory , and recent 
sexual ac
tivity  to decrease the risk for inclusion of a woman with an earl y undetected 
pregnancy . 
10.4.3. Woman of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until be coming postmenopa usal 
unless perma nentl y steri le (see below).
If fertility  is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cycle ca nnot 
be confirmed before the first dose of study  intervention, additional evaluation should be 
conside red.

PF-068829 61
Protocol C3421005
Final Protocol Ame ndment 1 ,
19May 2020
PFIZER C ONFIDENTIAL
Page 88Women in the following categor ies are not considered WOCBP :
1.Premenopausal female with 1 of the following:
Documented h ysterectomy ;
Documente d bilater al sal pingectomy ;
Documented bilateral oophorectom y.
For individuals with permanent infertility  due to analternate med ical cause other t han 
the above, (eg, mulleria n agenesis, androgen insensitivity ), investigator discretion 
should be applied to determini ng stu dy entry .
Note: Document ation for any  of the above categories can come from the site 
personnel’s review of the pa rticipant’s medical records, medical examination, or 
medical history  interview.   The method of documentation should be recorded in the 
particip ant’s medical record for the study .
2.Postmenopausal female :
A postmenopausal state is defined as age60yearsor older or no menses for 
12mont hs without an alt ernative medical cause. 
A high follicle -stimulating hormone (FSH) level in the po
stmenopau sal ra nge 
may be used to confi rm a postmenopausal state in women not using hormonal 
contraception or h ormonereplacemen ttherapy  (HRT). 
Females on HRT and whose menopausal status is in doubt will be required to use 
one of the nonestrogen hormonal highl y effecti ve contraception methods if they  
wish to continue their HRT during the stud y.  Otherwise, they  mustdiscontinue 
HRT to allow confi rmation of p ostmenopausal sta tus before stud y enrollment.
10.4.4. Contracepti onMethods
Highly Effective Methods That Have Low U ser De penden cy
1.Implantable pr ogestogen -only hormone contraception associated with inhibition of 
ovula tion.
2.Intrauterin
edevice (IUD) .
3. Intrauterine hormone - releasing s ystem (IUS) .
4.Bilateral tubal occlusion .
5.Vasectomized partner .

PF-068829 61
Protocol C3421005
Final Protocol Ame ndment 1 ,
19May 2020
PFIZER C ONFIDENTIAL
Page 89Vasectomized partn er is a highl y effective contraceptive method provided that the 
partner is the sole sexual partner of the WOCBP and the absence of sperm has 
been confirmed. If not, an addit
ional highl y effective method of contraception 
should be used.  The s permatogenesi s cycle is appr oximately  90 day s.
Highly Effective Methods That Are User Dependent 
1.Combined (estrogen- and pro gestogen- containi ng) hormonal contr aception as sociated 
with inh ibition of ovulation :
oral;
intravaginal ;
transdermal ;
injectable .
2.Progestogen -
only hormone contr aception associated with inhibition of ovulation:
oral;
injectable .
3.Sexual abstinence :
Sexual ab stinence is consi dered a highl y effective meth od only  if define d as 
refraining from heterosexual intercourse during the entire period of risk ass ociated 
with th e study  intervention. The reliability  of sexual abstinence needs to be 
evaluated in relation to the duration of the stud y and the preferred a nd usual 
lifesty le of the participant.
One of the following effective barrier metho ds must be used in addition to 
the highl y 
effective met hods listed above that are user dependent:
Male or female condom with or wi thout spermicide; 
Cervical cap, diaphragm, or sponge with spermicide; 
A combination of male condom with either cer vical cap, diaphragm, or sponge w ith 
spermicide (double-barrier m
ethods).

PF-068829 61
Protocol C3421005
Final Protocol Ame ndment 1 ,
19May 2020
PFIZER C ONFIDENTIAL
Page 90Collection of Pregnancy Information
For both unapproved/unlicensed products and for marketed produ cts, an exposure during 
pregnancy  (EDP) occurs if:
A female becomes, or i s found to be, pr egnant either whi le receiving or ha ving been 
exposed (eg, b ecause of treatment or environmental exposure) to the investigational
produ ct;or the female becomes or is found to be pregnant after discontinuing and/or 
being exposed to the inve stigational produ ct;
An example of environmental exp osure would be a case in volving direct contact 
with a Pfizer product in a pregnant woman (eg, a nur se reports that she is pregnant 
and has bee n exposed to chemotherapeutic products).
A male has been exposed (eg, because of treatment or en vironmental exposu re) to the 
investigation al product prior to or around the time of conception and/or is expose d 
during his partner’s pregnancy .
If aparticipan tor participant ’s partner 
becomes or is found to be pregnant during the 
partic ipant’s treatment with the investig ational pro duct, the inv estigator must report this 
information to Pfizer Safety  on the CT SAE Repor t Form and an EDP supplemental f orm, 
regard less of whether an SAE has occurred.
  In addition, the invest igator must submit
information rega rding environmenta l exposure to a Pfizer product in a pregnant woman (eg, a 
participant reports that she is pre gnant andhas been exposed to a cy totoxic product by 
inhalation or spillage) to Pfizer Safety using the EDP su pplemental form.  T his must be done
irrespective of w hether an A E has occurre d and within 24 hours of awareness of the 
exposure.  The information submit tedshould include the anticipat ed date of delivery  (see 
below for information related to termination of pregnancy ).
Follow- up is conducted to obtain general informatio n on the preg nancy  and its outcome for 
all EDP reports with an unknown outcome.  T he inv estigator will follow the pregna ncy until 
completion (or until pregnancy  termination ) and notify  Pfizer Safet y of the outc ome as a 
follow -
up to the initial E DP suppleme ntal form.  I n the case of a live birth, the structural 
integrit y of the neonate c an be 
assessed at the time of birth.  In the event of a termination, the 
reason(s) for termination should be s pecified and, if c linically  possibl e, the structural 
integrit y of the termina ted fetus should be assessed by  gross visual inspection (unless 
prepr ocedur e test findings are conclusive f or a congenital anomal y and the findings are 
reported).
If the outcome o f the pregnancy meets the criteria for an SAE (ie, ec topic pregn ancy, 
spontaneous abortion, intrauterine fetal demise, neonatal death, or congenit al anomal y [in a 
live-born bab y, a ter minated fet us, an intrauterine fetal demise, or a neonatal death]), the 
investigator shoul dfollow the proc edures for reporti ng SAEs.

PF-068829 61
Protocol C3421005
Final Protocol Ame ndment 1 ,
19May 2020
PFIZER C ONFIDENTIAL
Page 91Additional info rmation about pregnancy  outcomes that are reported to Pfizer Safet y as SAEs
follows: 
Spontaneous abortion includes mi scarriage and missed abortion;
Neonatal deaths that occur wit hin 1 month of bir th should be reported, without rega rd 
to causa lity, as SAEs .  In addition, infant deaths after 1 month should be reported as 
SAE s when the investigator assesses the i nfant death as related or possibly  related to 
exposure to the investigat ional product. 
Additional information regarding the EDP may  be requested by  the sponsor.  Further 
follow -up of birth outcomes will be handled on a case -by-case basis (eg, follow -up on
preterm in fants to identify  developmental delay s).  In the case of pate rnal exposure, the
investigator wil l provide the participant with the Pregnant Partner Release of Information 
Form to deliver to his partner.  The inves tigator must document in the sou
rce documents that 
the participant was given the Pregnant Partner Releas e of Information F orm to provide to his 
partner.

PF-068829 61
Protocol C3421005
Final Protocol Ame ndment 1 ,
19May 2020
PFIZER C ONFIDENTIAL
Page 9310.6. Appendix 6: Liver Safety: Suggested Actions and Follow -up Assessme nts 
Potential Cases of Drug -Induced L iver Injury
Humans exposed to a drug who show no sign of liver injury  (as determined by  elevations in 
trans aminases) are termed “tolerat ors,” while t hose who show transient liver injury , but adapt 
are termed “adaptors. ”  In some participant s, transaminase elevations are a harbinger of a 
more serious potential outcome.  These participant s fail t oadapt and there fore are 
"suscepti ble" to pro gressive and 
serious liver injury , commonl y referred to as drug -induced 
liver inju ry (DILI).  Participant s who experienc e a transam inase elevation above 3 times the 
upper limit of normal ( ×ULN) should be monit ored more frequen tly to determine i f they  are 
an“adaptor” 
or are “susceptible.”
In the majority  of DILI cases, elevations in as partat e aminotransferase (AST) and/or alanine 
aminotransferase (ALT) precede total bilirubin (TBili) elevation s (>2 ×ULN) by  several 
days or wee ks.  The increase in TBili ty pically occur s while AST/ALT is/are still elevated 
above 3 ×ULN (ie, AST/AL T and TBili values will be elevated within t he same lab oratory
sample).  In rare instances, by  the time TBili elevat ions are detected, AST/AL T values m ight 
have decrease d.  This oc currence is s till regarded as a potential DILI.  Therefore, abnormal 
elevations in eithe r AST OR AL T in addition to TBil i that meet the criteria outlined below 
are considered potential DILI (a ssessed per Hy ’s law criteria) case sand should alway s be 
consid
ered important medical events, even before all other possible causes of liver inju ry 
have b een excluded.
The threshold o f laborator y abnormalities for a potential DILI case depends on the 
participant ’s individu al baseline value s and underly ing conditions. Participant swho present 
with the following laboratory  abnormalities should be ev aluate d further as potential DILI 
(Hy’s law) case s to definitively  determine the etiology  of the abnormal labo ratory  values:
Participant s with AS T/ALT and TBili baseline valu eswithin the normal range who 
subsequently  present with AST OR AL T values >3 ×ULN AND a T Bili value 
>2×ULN with no e vidence of hemol ysis and an alkaline phosphatase value 
<2×ULN or not a vailable.
For participant s with bas eline AST OR ALT ORTBili val ues above the ULN, the 
following threshold values are used in the definition menti oned a bove, as needed, 
depending on wh ich values are above the ULN at baseline:
Preexisting AST or ALT baselin e values above the normal range: AST or ALT 
values >2 times the baseline values AND >3 
×ULN; or >8 ×ULN (whichever is 
smaller).
Preexisting valu es of TBili above the normal range: TB ili level i ncreased from 
baseline value b y an amount of at least 1 × ULN orif the value r eaches 
>3×ULN ( whichever is small er).

PF-068829 61
Protocol C3421005
Final Protocol Ame ndment 1 ,
19May 2020
PFIZER C ONFIDENTIAL
Page 94Rises in AST/AL T and TBili separated by  more than a few weeks should be assessed 
individ ually  based on clinical judgment; an y case where uncertainty  remains as to whether it 
represents a potential H y’s law case shoul dbe reviewed wit h the sponsor.  
The particip
antshould re turn to the investigator site and be evaluated as soon as possible, 
prefera bl y within 48 hours from awarene ss of the a bnormal results.  This evaluation should 
include laboratory  tests, detailed hist ory, and physica l assessment.  
Inaddition t o repeating m easurements of AST and AL T and TBili for suspected cases of 
Hy’s law,addit ional 
laboratory  tests should include album in, creatine kinase (CK), direct and 
indirect bilirubin, gamma- glutam yl transfe rase (GGT), prothrombin time (PT)/internationa l 
normalized ratio (INR), total bile acids, and alkaline phosphatase.  Consideration should also 
be given to drawing a s eparate tube of clotted blood and an anticoagulated tube of blood for 
further testing, as needed, for furth er contemporaneous analyses at the time of the recognized 
initial abnormalities to determine etiology.  A detai led hi story, including relevant 
inform ation, such as review of ethanol, acetaminophen (either b y itself or as a coformulated 
product in prescript ion or over -the-counter medic ations) , recr eational drug, supplement 
(herbal) use and consumption, family  histor y, sex ualhistory , travel history, his tory of con tact 
with a jaundiced person, surgery , blood transfusion, his tory of liver or a llergic disease, and 
potential occu
pational ex posure to che micals, should be collected.  Further testing for acute 
hepatitis A, B, C, 
D, and E infection and liver ima ging (eg, biliary  tract) and collection of 
serum sample for acetaminophe n drug and/or prot ein adduct levels may be warranted.
All cases demonstrated on repeat testing as meeting the laboratory  criteria of AST/AL T and 
TBili elevation defined above should b e considere d potential DILI (Hy ’s law) cases if no 
other reason for the liver function tes t
(LFT)abnormali ties has y et been found.  Such 
potential D ILI (Hy’s law) cases are to be reported as SAEs, irrespective of avai labili ty 
of all the results of the inv
estigations performed to determine etiology of the LFT 
abnormalities.
A potential DILI (Hy ’s law) case bec omes a confirmed c ase onl y after all resul ts of 
reasonable investigations have been received and have excluded an alt ernative etiology .

PF-068829 61
Protocol C3421005
Final Protocol Ame ndment 1 ,
19May 2020
PFIZER C ONFIDENTIAL
Page 9710.8. Appendix 8:Prohibited Prior/Con comitant Medicatio ns
The following medi cations are prohibited until the first follow- up visit (ie, Visit10, 
Week17-18), unless stated otherwise.  If a partici pant receives a prohibited medication, the 
investigator shoul d contact the Spon sor Clinician or Sponsor Medical Mo nitor to determine if
t
he participant may  remain in the study .  
Drug Class es and/or Drugs Timeframe of Restric
tion 
Prior to Screening Visit
Thiazolidinediones (TZDs) such as pioglitazone and rosigl itazone. 90 days
Subcutaneously ad ministered agents for glycemic control (eg, insulin, 
exenatide, liraglutide, dulagl utide, sem aglutide, pramlintide).  Note: Short -term 
(ie, ≤7days) of insulin administration is permitted if participant is hospitalized.90 days
Pharm acological agents with approved indica tion for weight loss such as 
liraglutide, orlistat and sibutramine.90 days
Oral anti -diabetic medications, including:
Sulfonylureas such as acetohexamide, chlorpropamide, tolazamide, 
tolbutami de, glimepiride, glipizide, glyburide. Note: These may be used as 
glycemic rescue medications (See Section 6.5.5 ).
Meglitinide analogues such as repaglinide, nateglinide.
Dipeptidyl peptidase 4 inhibitors (DPP 4i) such as sitagliptin, s axagliptin , 
linagliptin, vildagliptin.
glucosidase inhibitors such as acarbose, miglitol.
Sodium glucose cotransporter 2 (SGLT2) inhi bitors suc has canagliflozin, 
empagliflozin, dapagliflozin, ertugliflozin. Note: These may be used as 
glycemic rescue medications (See Section 6.5.5 ).
Anti-hyperglycemic medications, including brom ocriptin eand colesevelam.60 days
Systemic glucocorticoids such as prednisone, dexamethasone, triamcinolone, 
budesoni de, betame thasone.  Note: As an exception, steroid -containing 
inhalers, nasal sprays and topical formulations are permitted.   
Note: Intercurrent treatment with systemic corticosteroids during participation 
in the study may be permitted if treatment does/will not exceed 7 days.60 days
Immunosuppressants such as cyclosporine and tacrolimus. 60 days
Appetite or w eight modifying medication s, includi ng nonprescription or 
herbals and medical grade marijuana.60 days
Anti-psychotic medications such as olanzapine, risperidone. 60 days
Coumarin type anticoagulants or other anticoagulants ( eg, dabigatran). 60 days
Anticonvulsants if prescribed for seizu re disorder. 60 days
Antiarrhythmic medications whose primary mechanism of action is sodium or 
potassium channel blockade (eg , procainam ide, phenytoin, quinidine, 
propafenone; as well as amiodarone, dofetilide, sotalol).
Note : -adrenergic recep tor block ing agents (eg, atenolol, metoprolol) and 60 days

PF-068829 61
Protocol C3421005
Final Protocol Ame ndment 1 ,
19May 2020
PFIZER C ONFIDENTIAL
Page 98Drug Class es and/or Drugs Timeframe of Restriction 
Prior to Screening Visit
calcium channel blockers (eg, diltiazem, amlodipine, nifedipine) are permitted.
Sympat homimetic agents.
Note: Inhaled -adrenergic receptor agonists (eg albuterol) are permitted.60 days
BCRP Substrates .
Rosuvast atin.  Note: Other statins are permitted.
Sulfasalazi ne.Prohibited post
randomization
Use of CYP3A4/5 substrates with narrow  therapeutic index –eg, alfentanil, 
astemizole, cisapride, cyclosporine, dihydroergotamine, ergotamine, fentanyl, 
pimozide , quinidine, sirolimu s, tacrolimus, and terf enadine .Prohibited post
randomizat ion 
Use of chronic agents which are potent inducers of CYP3A (eg, rifampin) . Prohibited post 
randomization 
Use of chronic agents which are clinically significant OATP inhibi tors 
(eg,cyclosporin e, gemfibrozil, rifampi n).Prohib ited post 
randomization 
Use of potent 3A4 inhibitors . Prohibited post 
randomization 
Paclitaxel, torsemide, amodiaquine . Prohibited post 
randomization 

PF-06882961
Protocol C3421005Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 10010.10. Appendix 10: Abbreviations
The following is a list of abbreviations that may be used in the protocol.
Abbreviation Term
Abs absolute
AE adverse event
ALT alanine aminotransferase
AST as partate aminotransferase
AUC 24 area under the curve at 24 hours
AV atrioventricular
BBS Biospecimen Banking System
BCRP breast cancer resistance protein
β-hCG beta-human chorionic gonadotropin
BID twice daily
BMI body mass index
BP blood pressure
bpm beats per minute
BUN blood urea nitrogen
cAMP cyclic adenosine monophosphate
CFB change from baseline
CFR Code of Federal Regulations
CIOMS Council for International Organizations of Medical Sciences
CK creatine kinase
CKD-EPI Chronic Kidney Disease Epidemiology Collaboration
Cmax maximum observed concentration
CO 2 carbon dioxide (bicarbonate)
CONSORT Consolidated Standards of Reporting Trials
CRF case report form
CRO contract research organization
CSR clinical study report
CT clinical trial
%CV percent co efficients of variance
CYP cytochrome P450
DDI drug drug interaction
DILI drug-induced liver injury
DNA deoxyribonucleic acid
DU dispensable unit
EC ethics committee
ECG electrocardiogram
eCRF electronic case re port form
EDP exposure during pregnancy
eGFR estimated glomerular filtration rateCCI
PF-06882961
Protocol C3421005Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 101Abbreviation Term
EMA European Medicines Agency
EU European Union
EudraCT European Clinical Trials Database
FPG fastin g plasma glucose
FSH follicle-stimulati ng hormone
FT4 free thyroxine
GCP Good Clinical Practice
GGT gamma-glutamyl transferase
GLP-1 glucagon like peptide -1
GLP-1R glucagon like peptide -1 receptor
HAE hypoglycemic adverse event
HbA 1c glycated hemoglobin 
HIPAA Health Insurance Portab ility a nd Accountability Act
HIV human immunodeficienc y virus
HRT hormone replacement therapy
IB investigator’s brochure
IR immediate release
ICD informed consent document
ICH International Council for Harmonisation
ID identification
IMP investigational medicinal product
IND investigational new drug application
INR international normalized ratio
IP investigational product
IRB institutional review board
IRC internal review committee
IRT interactive response technology
IUD intrauterine device
IUS intrauterine hormone-releasing system
IV intravenous
IVGTT intravenous glucose tolerance test
IWR interactive Web- based res ponse
LBBB left bundle branch block
LFT liver function test
MAR missing at random
MATE multidrug and toxin extrusion protein
MCH mean corpuscular hemoglobin
MCHC mean corpuscular hemoglobin concentration
MCV mean corpuscular volumeCCI
CCI
CCI
PF-06882961
Protocol C3421005Final Protocol Amendment 1, 19 May 2020
PFIZER CONFIDENTIAL
Page 102Abbreviation Term
MDG mean daily glucose
MDR1 multidrug resistance mutation
MEN2 multiple endocrine neo plasia syndrome type 2
MMRM mixed model repeated measures
msec millisecond
MTC medullary thyroid carcinoma
N/A not applicable
NIMP noninvestigational medicinal product
NOAEL no-observed-adverse-effect level
OATP organic anion transporting polypeptides
OCT organic cation transporter
PCD primary completion date
PD pharmacodynamic(s)
PI principal investi gator
PR pulse rate
PT prothrombin time
PVC premature ventricular complex
QTc corrected QT
QTcF corrected QT (Fridericia method)
qual qualitative
RBC red blood cell
RNA ribonucleic acid
SAE serious adverse event
SAP statistical analysis plan
SC subcutaneous
SD standard deviation
SGLT2 sodium glucose co-transporter 2
SMP study monitoring plan
SoA schedule of activities
SOP standard operating procedure
SRSD single reference safety document
SSID study specific subject identification
SToD study team on demand
SUSAR suspected unexpected serious adverse reaction
t½ half life
T2DM type 2 diabetes mellitus
TBA total bile acids
TBili total bilirubin
TEAE treatment emergent adverse event
TI therapeutic index
Tmax time to maximal concentrationCC
I
PF-068829 61
Protocol C3421005
Final Protocol Ame ndment 1 ,
19May 2020
PFIZER C ONFIDENTIAL
Page 103Abbreviation Term
TSH thyroid stimulating hor mone
TZD thiazoledi ediones
UGT uridin e 5'-diphospho- glucur onos yltransferase 
glucuronosy ltrans ferase
ULN upper limit of normal
US United States
WBC white blood cell
WOCBP woman of childbearing potentia l

PF-068829 61
Protocol C3421005
Final Protocol Ame ndment 1 ,
19May 2020
PFIZER C ONFIDENTIAL
Page 10411.REFERE NCES
1. Ørskov C, Holst JJ, Knuhtsen S, et al. Glucagon-l ike pe ptides GLP -1 and GL P-2, 
predict ed produc ts of the glucagon gene, are secret ed separatel y from pig small inte stine 
but not pancreas. Endocrinology  1986;119(4):1467-75.
2. Krey mann B, William s G, Ghatei MA, et al. Glucagon - like peptide-1 7 -36: a 
physiolog ical i ncretin in man. Lancet 1987;2(8571):1300 -4.
3. Nauck MA, Niedereichholz U, Ett ler R, et al . Glucagon -like pepti de 1 inhibition of 
gastric empt ying outweighs its insulinotropic effects in he althy  human
s. Am J Phy siol 
1997;273(5):E981-8.
4. Flint A, Raben A, Astru p A, et al. Glucagon- like pepti de 1 prom otes satiet y and 
suppresses energy  intake in humans. J Clin I nvest 1 998;101(3):515 - 20.
5. Hu FB. Globalization of diabetes : the role of diet, lifesty le and gene s. Diabetes Ca re 
2011;34:1249-57.
6. IDF Diabetes Atlas; 8thEdition: http://www.idf.org/diabetesatlas <Accessed Feb 4, 
2019>. 
7. Menke A, Casagrande S, Geiss L , Cowie CC. 
Prevalence of and Trends in Diabetes 
Among Adults in the United States, 1988-2012. JAMA 2 015;314:1021.
8. DeFronzo RA. From 
thetriumvirate to the omin ous octet: a new pa radigm for t he 
treatm ent of t ype 2 diabetes mellitus. Diabetes 2009;58:773-95.
9. Stratton I M, Adler AI, Neil HAW, et al. Association of gl ycaemia with macrovascular 
and microvascul ar complicatio ns of ty pe 2 diabetes (UK PDS 35): prospective
observational stud y. BMJ 2000; 321:405-12.
10. Drucker, DL. The ascending GLP -1road from clinical safet y to red uction of 
cardiovascular complications. Diabetes 
(2018); 67: 1710-1719. 
11. Loren z et al. Differential eff ects of glucagon -like pep tide-1 receptor agonists on heart 
rate. Cardiovasc 
Diabetol (2017); 16:6.
12. VICTOZA [Package inse rt], Drugs@FDA. 2016 Apr., Availa ble: 
http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022341s025lbl.pd f 
<Accessed Feb 4 , 2019>.
13. Banholzer ML, Wandel C, Barrow P, et al. Cli nical trial conside rations on m ale 
contr aception and collection of pregnanc y information from female partner :update. 
Clin Transl Med 2016; 5(1):23-
37.

PF-068829 61
Protocol C3421005
Final Protocol Ame ndment 1 ,
19May 2020
PFIZER C ONFIDENTIAL
Page 10514. Levey  AS, Stevens LA, Schmid CH, Zh ang YL, Cas tro AF 3rd, Fe ldman HI, Kusek 
JW, Egger s P, Van Lente F, Gr eene T, Coresh J. A New Equati on to Est imate 
Glomerular Filtration Rate. A nn Intern Med. 2009; 150:604 -612.
15. American Diabetes Association. Standards of medical care in diabetes -2019. Diabetes 
Care. 2019 Jan;4 2(Suppl 1): S1- S193 .
16. ICH Harmonised Guideline E9 (R1); Estimands and Sensiti vity Anal ysis in Clinical 
Trials; 16 June 2017.
